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ABSTRACT OF THE DISSERTATION
Identification and Characterization of Rare Variants in Cholinergic Nicotinic Receptor
Genes and their Contribution to Substance Dependence.
by
Gabriel Emanuel Haller
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics Program
Washington University in St. Louis, 2013
Professor Alison Goate, Chairperson
Genome-wide association studies (GWAS) have identified common variation in
the CHRNA5-CHRNA3-CHRNB4 and CHRNA6-CHRNB3 gene clusters that contribute to
nicotine dependence. However, the role of rare variation in risk for substance dependence
in these nicotinic receptor genes has not been studied.
In order to investigate the role rare variants play in the development of nicotine
dependence, we undertook pooled sequencing of the coding regions and flanking
sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 genes in 710
African Americans (461 nicotine dependent (ND) cases and 249 smokers with no
symptoms of dependence (controls)) and 2055 European Americans (1062 ND cases and
993 controls) from the Collaborative Study of the Genetics of Nicotine Dependence
(COGEND). Carrier status of individuals harboring rare non-synonymous variants at
conserved sites in each of these genes was then compared in cases and controls to test for
an association with nicotine dependence. We find a reduced risk for nicotine dependence
among carriers of missense variants at conserved residues in CHRNB4 in African
Americans and European Americans.
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We next aimed to determine whether rare genetic variation in these genes
influence risk for developing alcohol or cocaine dependence, two conditions highly
comorbid with nicotine dependence. We undertook pooled sequencing of the coding
regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and
CHRNB3 genes in 287 African Americans (147 DSM-IV alcohol dependent cases and
140 controls) and 1028 European Americans (480 DSM-IV alcohol dependent cases and
548 controls) individuals from the Collaborative Study of the Genetics of Alcoholism
(COGA). For European Americans, we find increased DSM-IV cocaine dependence
symptoms (famSKAT p= 2x10-4) and increased DSM-IV alcohol dependence symptoms
(famSKAT p= 5x10-4) among carriers of missense variants in CHRNB3. For African
Americans, we find decreased cocaine dependence symptoms among carriers of missense
variants in CHRNA3 (famSKAT p= 0.006).
Finally, we sought to determine the functional impact of rare variants in CHRNB4
harbored by individuals in these two cohorts. A total of 10 variants in CHRNB4 observed
in the COGEND cohort were investigated. One variant in CHRNA3 was also functionally
tested as it is high linkage disequilibrium with another rare missense variant in CHRNB4.
We find several variants that alter cellular response either to nicotine or acetylcholine as
well as many variants that alter cell-surface protein expression as measured by cellsurface ELISA without altering either CHRNB4 mRNA or total β4 protein as measured
by western blot. Further, when we integrate these in vitro findings into a model of
association with nicotine dependence related traits, we improve the association,
suggesting that the success of future association analyses in these and potentially many
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other genes across the genome, may depend greatly on functional assessment of observed
genetic variation.
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Chapter 1. Introduction and Perspective1
Complex Trait Genetics
A complex genetic trait is defined as a heritable trait for which the genetic
contributors are not limited to one or a small number of genes. This is in stark contrast to
what geneticists refer to as “Mendelian” traits or diseases for which the genetic causes are
comparatively simple, being limited to one or a handful of genes or loci. Much effort in
the preceding decades has been spent trying to understand the genetic underpinnings of
complex traits. Before the advent of inexpensive single nucleotide polymorphism (SNP)
genotyping microarrays, limited numbers of variable sites across the genome were
interrogated either to ask very specific questions about genes with high prior probabilities
of contributing to a trait or to perform linkage scans in families to identify large genomic
regions segregating with disease/trait status. In each case, genes underlying complex
traits were identified, but with limited success. More recently, microarrays able to
genotype hundreds of thousands or millions of SNPs across the genome have been used
to identify thousands of common genetic variants contributing to complex disease risk.
So-called genome-wide association studies (GWAS) were then performed using these
genotyping arrays in large cohorts of cases, individuals with a given disease or trait, and
controls, individuals specifically ascertained to be free of disease or not have a given
trait1. The variants significantly associated with the tested diseases or traits have
generally had small effects, however, with individuals heterozygous at these sites having
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odds of developing disease of 1.1-1.5 compared to non-carriers. These small effect-sizes
have demanded that investigators increase sample size considerably in order to have the
statistical power necessary to find significant associations. One of the largest studies of a
complex trait, consisting of ~250,000 subjects, was for anthropomorphic traits such as
height and body-mass index (BMI; height/weight2) 2. This study was able to find 69
genome-wide significant SNPs associated with one of their traits of interest but were still
only able to explain ~5% of BMI with the genome-wide significantly associated SNPs
(Figure 1.1).
More recent studies of complex traits have utilized the newly developed method of
exome sequencing, i.e. only sequencing the protein-coding portion of the genome (~1.5%
of the genome)3-5 or have used genotyping microarrays designed to only interrogate the
protein-altering genetic variants (exome chip) . Exome sequencing involves using
genomic capture techniques, i.e. hybridizing sheared genomic DNA with biotinylated
RNA baits complementary to the protein-coding regions of the genome and then washing
away any DNA fragments that did not hybridize (Figure 1.2). For the exome-chip, only
protein-altering variants are genotyped that were found in multiple individuals from
~12,000 sequenced exomes and genomes culled from the 1000 genomes project 6, the
NHLBI Exome Sequencing Project7 and others. In each case, the population frequency of
variants is generally much lower than the frequency of variants investigated as part of
genome-wide association studies, as protein-altering variants are more likely to be
negatively selected in populations due to their increased probability of deleterious effects
and as a result are also more likely to be at low frequencies in populations 8. This reduced
population frequency, however, also reduces power to detect associations between
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complex traits and these variants 9. As such, very few of the studies utilizing these
methods have had much success identifying novel genes or loci underlying complex
disease. Even using collapsing methods wherein rare variants are combined to create
pseudo-common variants or using complex statistical frameworks, very few examples
exist of large exome-sequencing efforts that have yielded significant findings and many
of these have been for de novo variants in schizophrenia, autism and cancer 10-14. As
exome sequencing is still rather expensive, however, many of the exome sequencing
studies have been made of many small samples pieced together from disparate sources
and as such have lacked power. Regarding studies utilizing the exome-chip, the lack of
positive results may be in part due to the fact that rarer variants are harder to call using
currently available genotype clustering algorithms. The result of this is an increased
probability of incorrect genotyping calling which in turn increases both the false positive
and false negative rates in association testing done with the resultant genotypes. Very
few studies, therefore, have yet been published using exome-chip data 15.
Overall, complex genetic diseases have garnered substantial attention in the recent
past, but only small amounts of variability in the traits and diseases under study have
been explained using current techniques 16. This can be explained in part by a lack of
attention paid to rarer variants and in part due to a lack of power in all studies. It is likely
that complex traits and diseases are the product of hundreds if not thousands of variants
of all frequencies, many with near infinitesimal effect sizes. It will likely be important in
the future to develop ways of integrating knowledge of specific variant’s impact on
protein function or gene expression, etc. into models of association.
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Genetics of Nicotine Dependence
Substance abuse is one the leading causes of preventable death in the United States and
across the world. Cigarette smoking, for instance, dramatically increases risk of
developing lung cancer, chronic obstructive pulmonary disease (COPD), coronary heart
disease and stroke and is overall the number one cause of preventable death worldwide
2,17

. Figure 1.3 shows survival curves for individuals who either never smoked, used to

smoke or smoke differing numbers of cigarettes per day on average 18. Additionally,
alcohol dependence represents a considerable health and economic burden due to
substance use related morbidity, accidents and imprisonment 19. As such, it is critical to
understand the underlying causes of substance-related behavior and substance
dependence (SD). Studies have suggested that genes, the environment and the interplay
between the two play an important role in determining whether or not a person will
become substance dependent 20,21. For instance, an individual who has never been
exposed to nicotine cannot be nicotine dependent. If one is concerned with elucidating
genes underlying the effect of nicotine on smoking behavior, it is important to correct for
environmental factors whenever possible. It is clear from epidemiological studies and in
ascertaining individuals for genetic studies that there exist different strata of smokers.
There are those who have smoked cigarettes, but not enough to elicit sustained activation
of reward pathways in the brain (~22% of smokers), those who smoke regularly but show
few signs of being nicotine dependent (~33% of smokers) and finally those who show
high levels of nicotine addiction (~44% of smokers). Figure 1.4 shows the proportions of
individuals from a population-based sampling of individuals who made the various
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transitions to nicotine dependence and the heritability estimates for both smoking
initiation and nicotine dependence 22. Additionally, because there is strong comorbidity
among types of substance dependence and it is thought that though there are substance
specific genetic and environmental risk factors, some evidence suggests that much of the
genetic vulnerability to different substances is shared 23,24.
Using the Fagerström Test for Nicotine Dependence (FTND), a quantitative
measure of nicotine dependence can be calculated 25,26. The FTND questionnaire consists
of six questions (4 one point questions and 2 three point questions) giving a maximum
score of 10 for individuals with strong nicotine dependence (Figure 1.5). A major
component of the FTND is the number of cigarettes smoked per day (CPD), one of the
two three point questions, making CPD another quantitative measure of nicotine
dependence similar to and highly correlated with FTND score. Additionally, we can, I we
do for our studies, exclude all individuals who have never smoked at least 100 cigarettes
in their life. This corrects for the GxE interaction between nicotine exposure and
associated gene variants with respect to nicotine dependence. It is for these reasons that
we will choose individuals to sequence from the extremes of FTND score and CPD.
Studies of families and twins have suggested a strong genetic contribution to the
development of multiple nicotine related traits. One such study found that ~50% of the
variance in smoking persistence could be accounted for by genetic factors 27.
Additionally, age of initiation was also found to be highly heritable 28. A meta-analysis of
several twin studies also identified a role for genetics in the initiation of smoking 29. A
number of heritability studies have investigated generalized drug addiction, often
including nicotine dependence as one of the drugs on which an individual could be
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dependent. One such study found that there was as much as an 8-fold increase in risk for
relatives of drug-dependent individuals compared to individuals without drug-dependent
relatives 30. Twin studies have also given credence to the genetic contributions to
smoking behavior. Many groups have found that the concordance for smoking was
significantly higher in monozygotic male twin pairs than in dizygotic male twins 27,31-34.
Genetic variation in the cholinergic nicotinic receptor genes (CHRNs) has
repeatedly been found to be highly associated with nicotine dependence (see 35 for
review). The first report of variants in nicotinic receptor genes contributing to nicotine
dependence was a candidate gene study performed by members of our group 22,36. The
most compelling association from that study was with a SNP near CHRNB3 on
chromosome 8 in humans. However, they were also the first to report an association
between the non-synonymous SNP rs16969968 (D398N in the a5 nicotinic receptor
subunit gene). Despite big differences in the frequency of this SNP across populations, it
shows a similar effect on risk, with odds ratios 1.3-2.00 in European, African American
and Asian populations 37,38.
Notably, nicotinic receptor genes often form gene clusters. CHRNA5, CHRNA3 and
CHRNB4 on chromosome 15 and CHRNA6 and CHRNB3 on chromosome 8 are directly
adjacent to each other (Figure 1.6). This is of particular note, as at least some of these
genes seem not to have evolved from tandem duplications, but rather most likely came
together having been duplicated elsewhere to exist in close proximity on one haplotype
block so that they could be co-regulated. If a phylogenetic tree is constructed using the
amino acid sequences of all human nicotinic receptor paralogs, it is clear that the alpha
subunits are more closely related to each other than to any beta subunit and that CHRNA3

	
  

6	
  

shares more similarity to other alpha subunits than to CHRNA5, its closest physical
neighbor (Figure 1.7). The hypothesis that these genes are co-regulated is confirmed in
part when one considers the construction of “tabak” mice, constructed to possess a
transgenic region encompassing all of the genes in the cluster, including non-coding
regions 39. These mice overexpress chrnb4 and express an eGFP-chrna3 hybrid protein in
precisely the regions of the brain that express the genes endogenously, suggesting that the
surrounding non-coding DNA alone is sufficient to determine brain expression patterning.
Since the discovery of the role of rs16969968 in nicotine dependence, multiple
independent variants near the CHRNA5 gene have been identified that contribute to
smoking related phenotypes. The discovery of these variants was in part motivated by
the presence of other nicotinic receptor genes in the region of association. A group of
highly correlated variants including the SNP rs588765 near CHRNA5 was recently shown
to increase CHRNA5 mRNA expression and increase risk of nicotine dependence
independently of rs16969968 40,41. Additionally, a group of SNPs tagged by rs1996371
near the CHRNB4 gene was shown to affect age of onset of daily smoking 42. Of note,
this variant is not in high linkage disequilibrium (r2) with either the common nonsynonymous variant in CHRNA5 (rs16969968) or the variants correlated with CHRNA5
mRNA (tagged by rs588765), suggesting as many as three independent associations
between smoking related phenotypes and variants in this region. The common variants at
the CHRNA6-CHRNB3 gene cluster as well as the common variants at the CHRNA5CHRNA3-CHRNB4 gene cluster tagged by rs16969968 were also recently shown to
contribute to smoking quantity in several large meta-analysis genome-wide association
studies 43,44. Together these results strongly suggest multiple mechanisms connecting
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nicotinic receptor function to nicotine dependence and nicotine related behaviors. Despite
these findings, only a small proportion of the variance (~5%) in nicotine dependence
related traits has been explained by these variants 45.
The same genome-wide association study meta-analysis that identified variants in
the CHRNA6-CHRNB3 and CHRNA5-CHRNA3-CHRNB4 gene clusters, also identified a
group of variants near the CYP2A6 gene (tagged by rs4105144) that were genome-wide
significantly associated with cigarette consumption 43. The CYP2A6 gene was an ideal
candidate for such a study as it is the major hepatic nicotine-metabolizing enzyme in
humans. There are several variants in or near CYP2A6 that reduce enzymatic activity and
others that are highly associated with rate of nicotine metabolism 44,46. The GWA
associated SNP is in LD with CYP2A6*2 (rs1801272) (r2 = 0.13 and D′ = 1.0 in the
HapMap CEU samples) and the CYP2A6*2 reduced-function allele is only found on the
background of the minor allele of rs4105144, associated with reduced smoking quantity.
Further, our group has demonstrated that an allele defined by harboring a large deleted
segment containing this SNP is also in complete LD (D’=1) with the GWA associated
SNP. This not only suggests that the SNP rs4105144 is tagging several reduced-function
variants, but that its association may have been partially exaggerated by having some
hemizygous individuals who are heterozygous for rs4105144 appear as minor allele
homozygotes.

Rare Variant Associations
Rare genetic variants have recently been shown to contribute to a number of
common human diseases (see 47 for review). Multiple rare variants have been reported in
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genes previously shown to harbor common variants associated with common diseases 4850

. Additionally, studies have demonstrated associations between rare variation in

nicotinic receptor genes and nicotine dependence 51,52. As a class, rare SNPs, copynumber variants (CNVs) and small insertion/deletion polymorphisms (indels) constitute
the majority of human genetic variation and thus may hold the key to understanding part
of the missing heritability of complex traits unaccounted for by recent genome-wide
association studies. Sequencing is one of the few methods by which these variants can be
investigated; however, the cost of sequencing hundreds or thousands of individuals for
multiple genes remains high despite advances in sequencing technologies. An efficient
alternative approach is to carry out DNA sequencing using DNA pooled from multiple
individuals. Alternatively, whole exomes have recently become a relatively efficient
method of performing gene-based, rare variant associations in an unbiased manner across
the genome. This technique was first utilized for the identification of rare Mendelian
diseases, but has recently expanded into gene-based genome-wide searches for common
complex diseases. One of the first Mendelian disorders to be mapped using this method
was Kabuki syndrome 4. The identification of the gene underlying this disorder was
relatively straightforward, however, as it is recessive and thus required each affected
individual to be either homozygous or a compound heterozygote for the same gene, a
condition that is not met with high probability in the general population. Efforts have
been far less successful for common complex, however, likely due to the limited power
afforded by small sample size when using collapsed non-synonymous variants. Such
variants are exceedingly rare, especially in genes with even moderate levels of crossspecies conservation, and as such require large sample sizes to obtain sufficient power to

	
  

9	
  

detect an association. Candidate gene studies have had more success than whole-genome
scans, likely due to the reduced burden of multiple testing. A study of five genes requires
a modest p-value of 0.01 to reach statistical significance, while an exome sequencing
study requires a p-value of 2.5x10-6 assuming 20,000 genes to reach statistical
significance.
Methods for the analysis of multiple rare variants with regards to complex traits are
still in their infancy. A number of studies have suggested strategies for investigating rare
variants. Among these are the cohort allelic sums test (CAST), combined multivariate
and collapsing (CMC), weighted sum (WS), c-alpha, variable threshold (VT) and SKAT
methods 9,53-55. Each technique combines multiple alleles to create aggregate genotypes,
scores or linear models to be used in a test of association. In the case of the CAST
method, the number of individuals with at least one mutation at a locus is compared in
cases and controls. This is by far the simplest method, but has limitations. For the CMC
method, rare variants are collapsed and then used with all common (≥5%) variants in a
multivariate analysis. One of the more intriguing techniques developed thus far for
detecting rare variant associations is the weighted sum method. In this method, variants
are weighted in proportion to the inverse of their frequency and each weighted variant
present in an individual is summed to form a person’s score. The scores of cases and
controls are then compared by permutation. One aspect lacking in each of the
aforementioned methods is some measure of the likelihood of functional impact for each
of the variants used in the analysis. For instance, evolutionary conservation, regional
genetic diversity or an actual measure of function for each variant would likely improve
power if integrated into one of these analyses. One of the largest problems facing human
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geneticists is how to determine what genetic variation present in a population is
functional, in particular whether variants are functional with respect to the phenotype
under study. The weighted sum method implicitly claims a relationship between variant
frequency and the probability that the variant has functional consequences. This is a valid
claim as far as sites under negative selection will tend to have reduced frequency
compared to neutral sites. However, some variants are rare because they entered the
population only a short time ago; they have not had sufficient time to be acted upon by
either genetic drift or natural selection. A more direct estimate of a site's probability of
function is its level of evolutionary conservation. Conservation is a proxy for functional
constraint and the presence of negative selection. I have previously described a method
using Tajima’s D, a measure of genetic diversity compared to divergence, to compare
case and control allele frequency spectra at a locus 49. Another possibility would be to
weight variants as in the weighted sum method but by likelihood ratio test (LRT) score, a
measure of conservation, rather than by frequency 56. Recently, progress in the field of
rare variant association testing was made with the introduction of the sequence kernel
association test (SKAT) 55,57 and the c-alpha test 56. In the case of SKAT, the test is a
score-based variance-component test that takes into account both rare and common
variants. One limitation of collapsing methods is that if neutral common alleles are
collapsed with even rare alleles with large effects, the common variant will mask the
effects of the rare alleles. This is overcome at least in part by SKAT in that alleles are
tested independently within the framework. For the c-alpha test, the distribution of allele
frequencies is compared between cases and controls. Whether rare alleles occur more
frequently in cases or controls, the distribution of alleles between cases and controls is
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skewed and will be identified. Despite the success these methods have afforded
researchers in the field, further work is necessary to perfect tests of rare variant
association and improve our ability to detect these rare variants often with modest effect
sizes.
Recently, several groups have interrogated the contributions of rare genetic
variants in select nicotinic receptor genes. Specifically, one group sequenced the
CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNB2,
CHRNB3, and CHRNB4 genes in ~1200 European Americans and another sequenced the
CHRNA4 gene in ~200 ND cases and ~200 controls and the fifth exon of CHRNA4 in
around 1000 additional ND cases and 1000 additional controls 51,52. Together, these
groups were only able to observe modest associations between nicotine dependence and
variants, either singly or collapsed across rare variants. They may have been limited by
having used only European Americans, however, as African Americans are known to
harbor a larger proportion of rare variation as they did not go though a recent population
bottleneck. These results highlight the need for more thorough investigation of rare
genetic variation in these nicotinic receptor genes with respect to susceptibility to
nicotine dependence.

Genetics of Alcohol and Cocaine Dependence
Twin and adoption studies have suggested that in addition to genetic variants that
contribute to risk of becoming dependent on a specific drug, there exist genetic factors
underlying a generalized risk for becoming dependent on multiple substances (see 58 for
review). Two such studies compared the rates of drug use for several commonly used
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substances over time in a cohort of monozygotic (MZ) and dizygotic (DZ) twins, finding
that the strong correlation observed between several drug dependence phenotypes could
be accounted for in part by shared genetic factors 59,60. The findings suggest that there
likely exist variants that contribute to risk for multiple drug dependence phenotypes
independently and that it is therefore possible that variation in nicotinic receptor genes,
despite having a clear mechanism of action with respect to nicotine dependence, may
contribute to risk for other drug dependences.
Epidemiological studies have shown high levels of comorbidity among alcohol,
cocaine and nicotine dependence 23. As such, it has been difficult to disentangle the
effects of genetic variants on each of these phenotypes. Numerous studies have found that
variants altering the function or expression of neuronal cholinergic nicotinic receptors
(CHRNs) alter risk for becoming nicotine dependent and several have shown effects of
variants in nicotinic receptors on risk for both alcohol and cocaine dependence (see 35 for
review). It is unclear from some of these studies, however, how much of the association
with a specific phenotype is due to the effect of the variant on nicotine versus alcohol or
cocaine. Common single nucleotide polymorphisms (SNPs) in CHRNA5 and CHRNB3
have been shown to be associated with nicotine dependence or nicotine consumption and
the most strongly associated SNP in several GWAS of nicotine dependence, a nonsynonymous change (rs16969968/D398N) in CHRNA5, has been shown to also affect
risk for cocaine dependence 61,62. Additionally, a highly correlated group of variants near
CHRNA5 previously shown to alter CHRNA5 mRNA expression in vivo, alter risk for
alcohol dependence 41. A group of common SNPs near the CHRNB3-CHRNA6 gene
cluster were also shown to affect cigarette consumption in a recent GWAS 43. Together,
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common variants explain only a small proportion of the variance (~1%) in alcohol or
cocaine dependence 45. The Diagnostic and Statistical Manual of Mental Disorders
Version IV (DSM-IV) is commonly used to assess and define alcohol dependence. The
DSM-IV defines alcohol dependent cases as individuals who endorse three (or more) of
the 7 symptoms of alcohol dependence at any time in the same 12-month period. Using
these criteria, we and others have identified a number of loci across the genome either
implicated in susceptibility to alcohol by linkage or by association. Among these are
several variants in gamma-amino butyric acid receptors (GABRA), alcohol dehydrogenase
(ADH), aldehyde dehydrogenase (ALDH), the mu opioid receptor (OPRM1) and bitter
taste receptors (TAS) genes (see 63 for review). Only two loci have been implicated in
alcohol dependence at the genome-wide significant level (< 5x10-8 ): A missense variant
(rs1229984; R48H) in the ADH1B gene and a bin of common SNPs tagged by
rs12912251 near C15orf53 64. Most of the other loci have only been weakly implicated as
risk factors for alcohol dependence.
As for alcohol dependence, several candidate loci have been implicated in risk for
cocaine dependence either by linkage or association studies 65-73. Among these are two
opioid receptor genes (OPRM1 and OPRD1), genes involved in serotonin and dopamine
systems like the 5-hydroxytryptamine (serotonin) receptor 1B gene (HTR1B) or the
dopamine receptor D2 (DRD2), as well as a number of other candidate genes. Unlike
alcohol dependence, no variant to date has been genome-wide significantly associated
with cocaine dependence 74. This is because no genome-wide association study of
cocaine dependence has been performed. Additionally, it is unclear how many of these
genetic factors are contributing to cocaine dependence specifically or whether these
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variants are affecting risk through their effects on susceptibility to other comorbid traits
or on a generalized effect on drug dependence.

Functional Studies of Nicotinic Receptors
Neuronal nicotinic acetylcholine receptors are pentameric ion channels produced from
various combinations of α and β receptor subunits and are the main target for nicotine in
the brain (Figure 1.8-1.10). The vast majority of neuronally expressed nicotinic receptors
contain the α4 and β2 subunits, but many other combinations are formed and have
distinct properties and expression patterns. Figure 1.8 shows the distribution of various
nicotinic receptor subunit combinations in the mouse brain. Many studies have
interrogated the effects of altering either nicotinic receptor amino-acid sequence or
expression level. Several nicotinic receptor genes have been characterized in mice by
knocking out the gene or transgenic overexpression and several variants observed in
human populations have been cloned and overexpressed to determine their effects using
electrophysiological methods or calcium flux assays. To date, the Chrnb2, Chrnb4,
Chnra6, Chrna4, Chrna7, Chrna3 and Chnra5 genes have been knocked out and the
CHRNB4 gene has been overexpressed in mice 75. There are profound effects on nicotineinduced behaviors in each case, strengthening the now well-established role of nicotinic
receptors in determining the physiological effects of nicotine. The specifics regarding the
role of each nicotinic receptor subunit are quite wide-ranging, however, though there are
commonalities. For instance, both the deletion of Chrna5 and the deletion of Chrnb4
results in resistance to nicotine induced seizures 76,77. At extremely high doses of nicotine,
mice will enter an epileptic state. Mice lacking either of these genes can be administered
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doses far exceeding the dose required to induce seizures in wild-type mice without
noticeable effects. Many other drug related and behavioral changes are apparent in mice
either lacking or overexpressing neuronal nicotinic receptor subunits. While knockout
mice for β2, α4 or α6 nicotinic subunits did not self-administer nicotine, there is no
difference between α7 knockout mice and wild-type as far as nicotine self-administration
78-81
39,77

. In contrast, mice lacking Chrna5 demonstrate enhanced nicotine self-administration

. With regard to drug independent behavioral changes, several nicotinic receptor

knockout lines show differences from wild-type mice. For instance, locomotor behavior
can be assessed in an open field test and can be categorized as being more navigational or
more exploratory. Using this test, β2 knockouts show a shift toward navigation to the
detriment of exploration 82. Re-expressing this subunit in the ventral tegmental area via
lentiviral rescue was able to normalize this phenotype, suggesting the role of β2 subunits
in this brain region in balancing these two aspects of locomotor behavior83,84.
A number of in vitro studies of variants in nicotinic receptor genes have been
performed in order to assess the functional impact of genetic variants on the receptors
harboring them. The three major techniques for performing these assays are: 1) voltageclamp of HEK cells transiently or stably transfected with expression vectors containing
wild-type or mutant nicotinic subunits, 2) voltage-clamp of xenopus oocytes injected with
either wild-type or mutant mRNA and 3) calcium flux assays that utilize aequorin, a
composite of the apoprotein apoaequorin and the prosthetic group coelenterazine, to
assess agonist induced calcium influx. One such assay was used to demonstrate that
receptors including the amino acid encoded by the minor/risk allele of the SNP
rs16969968 (CHRNA5 D398N) show a reduced response to the nicotinic agonist,
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epibatidine 85. These findings are in contrast, however, to results from whole-cell patch
clamp of HEK293 cells stably expressing α3 and β4 nicotinic receptor subunits,
transiently transfected with either the 398D or 398N form of the α5 nicotinic subunit 86.
This study was not able to observe a significant difference between the normal and
variant form of the receptor. Recent findings from our group have suggested that a high
extra-cellular concentration of calcium is necessary to observe the effect, a condition met
as a requirement of the experimental setup for the calcium flux assay used to demonstrate
the functional effect of the SNP initially 87.
Several variants in the CHRNB4 gene have been shown to affect receptor function
using one of these in vitro assays 88. The CHRNB4 variants T91I, R136W, S140G, and
M467V were each expressed heterologously in Xenopus oocytes and studied using the
two-electrode voltage clamp. These experiments revealed that the 136W and 467V forms
of the receptor had higher sensitivity to acetylcholine and lower EC50 than the wild-type.
The T91I variant was shown to have lower sensitivity to acetylcholine and a larger EC50.
Each of the T91I, R136W, and M467V variants also showed greater desensitization after
long-term exposure to low-dose acetylcholine.
One study of human carriers of the CHRNA5 D398N variant using resting-state
functional MRI found that carriers of the 398N allele had decreased intrinsic resting
connectivity strength in the dorsal anterior cingulate–ventral striatum/extended amygdala
circuit 89. Though, as mentioned before, the vast majority of neuronally expressed
nicotinic receptors contain the α4 and β2 subunits, many other combinations are formed
and have distinct properties and expression patterns. It is thought that the various aspects
of nicotine dependence (craving, withdrawal, tolerance, sensitivity, etc.) may be due to
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these distinct characteristics. For example, recent studies have shown that mice lacking
Chrna5 fail to display the adverse effects of high doses of nicotine and mice lacking
Chrnb4 or Chrna5 show reduced somatic signs of withdrawal after ceasing long-term
nicotine treatment 77,90. Additionally, mice over-expressing Chrnb4 were recently shown
to display a strong aversion to nicotine, that can be reversed by virally mediated
expression of α5 D398N variant in the medial habenula 39. This work suggests that the
aversive effects of nicotine in mouse are regulated by the balanced activity of ß4 and α5
nicotinic receptor subunits in the medial habenula. A recent association study of smoking
cessation also suggests that variants in CHRNB4 may decrease craving and withdrawal
symptoms 91.These findings suggest that multiple nicotinic receptor subunit genes likely
play a role in the development and maintenance of nicotine dependence and that variants
in these genes may have different and in some cases opposing functional effects in
humans and mice.
In addition to mediating the effects of nicotine, neuronal nicotinic receptors have
also been shown to alter the cellular and behavioral effects of alcohol independently of
nicotine 92-114. In vitro studies have shown altered response to ethanol upon perturbation
of nicotinic receptors in neurons 95,106-108,115. Studies in rats have extensively shown that
partial agonists of α4β2* or α3β4* nicotinic receptors affect alcohol consumption in vivo
92,95-98,101-105

. These results were confirmed and expanded using transgenic and knockout

mice of various nicotinic receptor genes 93,94,109-114. Further, one recent human trial found
that the α4β2 subunit partial agonist Varenicline was able to reduce alcohol consumption
among smokers 116. Together these results suggest that altered nicotinic receptor function
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likely has an effect on alcohol consumption independent of its effect on nicotine
consumption.
Conclusions
Overall, work on the genetic basis of substance dependence, in this case nicotine,
alcohol and cocaine dependence, has provided evidence that variants in the neuronally
expressed nicotinic receptor genes can contribute to risk for these substance dependences.
Work from many in the field has demonstrated that rare variation in genes may be able to
explain a substantial proportion of the heritability still missing despite massive metaanalysis efforts to uncover common variants underlying common disease. Together, these
results suggest that interrogation of the role of rare coding variation in the neuronal
nicotinic receptor genes will likely aid our understanding of the role of these genes in the
etiology of substance dependence. In the following chapters, I will describe how we
undertook sequencing of the most promising nicotinic receptor genes, those previously
implicated by genome-wide association studies to be involved in nicotine dependence, to
characterize the role of rare protein-altering variation in substance dependence risk. We
hypothesize that rare variants in the 5 nicotinic receptor genes contained within the two
gene clusters previously implicated in genome-wide associations studies, CHRNA5,
CHRNB4, CHRNA3, CHRNA6 and CHRNB3, harbor rare coding variation associated
with substance dependence, specifically nicotine, alcohol and cocaine dependence.
Furthermore, as work to improve our ability to detect rare variant association has
suggested that our ability to differentiate between protective, neutral and risk alleles will
substantially improve our ability to both find and understand rare variant associations, I
will describe how we functionally characterized all observed protein-altering variation in
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CHRNB4 to investigate incorporating the observed functional impact of specific variants
could improve our understanding of how these rare variants are affecting substance
dependence risk. We hypothesize that incorporation of such information will enhance
our association signal.
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Figure 1.1. Variance Explained at Differing uncorrected P-value Thresholds. Figure is
take from 2. A) Studies using only the extremes of BMI B) Studies using BMI as a
quantitative trait. Solid line is variance explained at each level of significance in the
meta-analysis of all listed constituent studies.
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Figure 1.2. Genomic Capture Strategy. Genomic DNA is prepared and hybridized with a
library compared of biotinylated RNA complementary to regions of the genome to be
captured. DNA-RNA hybrids are then incubated with streptavidin coated magnetic beads.
All DNA not hybridized with the biotinylated-RNA is then washed away. The retained
DNA is then amplified and sequenced. Figure is taken from:
http://www.genomics.agilent.com/.
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Figure 1.3. Survival of men who either never smoked, are ex-smokers or smoked varying
numbers of cigarettes per day on average. For example, ~65% of men who smoked ≥ 25
cigarettes per day lived to be 65 years old. Figure is taken from 18.
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Figure 1.4. Proportion of individuals transitioning from various steps in the progression
to nicotine dependence. The heritabilities of the smoking initiation (left) and nicotine
dependence (right) are shown in red. Dependence is based on the FTND scale. Data is
from20,85.
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Figure 1.5. Fagerström Test of Nicotine Dependence. Each question is worth 1 or 3
points and the sum of the points assigned based on answers provided are summed to form
a score from 1-10. A score above 4 confers a diagnosis of nicotine dependence
Information is from 25,26.
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Figure 1.6. Genomic context of sequenced genes. Positions are from human genome
reference assembly build 36.1 (hg18). Direction of transcription is designated with an
arrow. Exons are show as squares.
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Figure 1.7. Phylogenetic tree of nicotinic receptor cDNA sequences. Two subunits are in
a cluster on chromosome 8 (red) and three subunits form a cluster on chromosome 15
(green). The most abundant subunit combination is highlighted in orange and muscle
alpha and beta nicotinic receptor subunits are highlighted in blue. Figure was created
using the ClustalW program 117.
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Figure 1.8. Regional distribution of nicotinic acetylcholine receptors. (a) Subunit
combinations were deduced either by binding, immunoprecipitation and/or
immunopurification assays or from in situ hybridization, single-cell PCR and binding
studies of tissues obtained from rat and/or wild-type and/or knockout mice. * refers to
any of many possible subunits. Figure is taken from 118.
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Figure 1.9. Cytisine resistant 125I-epibatidine binding. Slices of brains from mice
overexpressing chrnb4 were incubated with cytosine and subsequently subjected to 125Iepibatidine. Darker areas correspond to increased epibatidine binding not bound by
unlabeled cytisine, which preferentially binds alpha4-beta4 containing receptors. Figure
is taken from 39.
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Figure 1.10. Nicotinic acetylcholine receptor configuration within the cell membrane
(green). Subunits (red) form pentameric ion channels. Upon binding of acetylcholine
(ACh) or other agonists, the pore is opened and the cell is depolarized. Binding of agonist
(yellow circles) occurs at the interface between alpha and beta subunits in the case of
heteromeric receptors. Figure is taken from 75.
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Chapter 2. Identification of rare variants in cholinergic nicotinic receptor genes and
their association with nicotine dependence2
ABSTRACT
Genome-wide association studies (GWAS) have identified common variation in the
CHRNA5-CHRNA3-CHRNB4 and CHRNA6-CHRNB3 gene clusters that contribute to
nicotine dependence. However, the role of rare variation in risk for nicotine dependence
in these nicotinic receptor genes has not been studied. We undertook pooled sequencing
of the coding regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4,
CHRNA6 and CHRNB3 genes in African American and European American nicotine
dependent smokers and smokers without symptoms of dependence. Carrier status of
individuals harboring rare missense variants at conserved sites in each of these genes was
then compared in cases and controls to test for an association with nicotine dependence.
We find a reduced risk for nicotine dependence among carriers of missense variants at
conserved residues in CHRNB4 in African Americans and European Americans (AA p
=0.0025, OR=0.31, 95% CI=0.31-0.72; EA p=0.023, OR=0.69, 95% CI=0.50-0.95). We
note that given the possibility of stochastic differences in rare allele frequencies between
groups replication is necessary to confirm these findings.
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INTRODUCTION
Genetic variation in the cholinergic nicotinic receptor genes (CHRNs) has repeatedly
been found to be highly associated with nicotine dependence (see 35 for review). Multiple
independent variants have been identified that contribute to smoking related phenotypes.
Among these, the most strongly associated single nucleotide polymorphism (SNP) in
several genome-wide association studies (GWAS) of nicotine dependence and correlated
traits is a common non-synonymous change (rs16969968/D398N) in CHRNA5 43. Despite
big differences in the frequency of this SNP across populations it shows a similar effect
on risk, with odds ratios 1.3-2.0 in European, African American and Asian populations
38,119

. In vitro functional studies have demonstrated that receptors including the amino

acid encoded by the minor allele, which is the risk allele, show a reduced response to the
nicotine agonist, epibatidine 85. Human carriers of the minor allele show decreased
intrinsic resting connectivity strength in the dorsal anterior cingulate–ventral
striatum/extended amygdala circuit 89. Additionally, a group of highly correlated variants
including the SNP rs588765 near CHRNA5 were shown to increase CHRNA5 mRNA
expression and increase risk of nicotine dependence independently of rs16969968 41,45.
Common variants at the CHRNA6-CHRNB3 gene cluster were also recently shown to
contribute to smoking quantity 43. Together these results strongly suggest multiple
mechanisms connecting nicotinic receptor function to nicotine dependence. Despite these
findings, only a small proportion of the variance (~5%) in nicotine dependence related
traits have been explained by these variants 45. Neuronal nicotinic acetylcholine receptors
are pentameric ion channels produced from various combinations of α and β receptor
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subunits and are the main target for nicotine in the brain. The vast majority of neuronally
expressed nicotinic receptors contain the α4 and β2 subunits, but many other
combinations are formed and have distinct properties and expression patterns. As such, it
is thought that the various aspects of nicotine dependence (craving, withdrawal, tolerance,
sensitivity, etc.) may be due to these distinct characteristics. For example, recent studies
have shown that mice lacking Chrna5 fail to display the adverse effects of high doses of
nicotine and mice lacking Chrnb4 or Chrna5 show reduced somatic signs of withdrawal
after ceasing long-term nicotine treatment 77,90. Additionally, mice over-expressing
Chrnb4 were recently shown to display a strong aversion to nicotine, that can be reversed
by virally mediated expression of α5 D398N variant in the medial habenula 39. This work
suggests that aversion of nicotine in mouse is regulated by the balanced activity of ß4 and
α5 nicotinic receptor subunits in the medial habenula. A recent association study of
smoking cessation also suggests that variants in CHRNB4 may decrease craving and
withdrawal symptoms 91. These findings suggest that multiple nicotinic receptor subunit
genes likely play a role in the development and maintenance of nicotine dependence and
that variants in these genes may have different and in some cases opposing functional
effects.
Rare genetic variants have recently been shown to contribute to a number of common
human diseases (see 47 for review). Specifically, multiple rare variants have been reported
in genes previously shown to harbor common variants associated with common diseases
48-50

. Additionally, studies have demonstrated associations between rare variation in

nicotinic receptor genes and nicotine dependence51,52. As a class, rare SNPs, copynumber variants (CNVs) and small insertion/deletion polymorphisms (indels) constitute
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the majority of human genetic variation and thus may hold the key to understanding part
of the missing heritability of complex traits unaccounted for by recent genome-wide
association studies. Sequencing is one of the few methods by which these variants can be
investigated; however, the cost of sequencing hundreds or thousands of individuals for
multiple genes remains high despite advances in sequencing technologies. An efficient
alternative approach is to carry out DNA sequencing using DNA pooled from multiple
individuals. To test the hypothesis that rare variants in the CHRNA5, CHRNA3, CHRNB4,
CHRNA6 and CHRNB3 genes influence risk for nicotine dependence we have employed
pooled sequencing in individuals with and without nicotine dependence in both European
Americans and African Americans. We report that rare (<5%) missense variants at
conserved sites in CHRNB4 are associated with decreased risk of developing nicotine
dependence and decrease the number of cigarettes consumed daily by smokers. These
findings demonstrate that nicotine dependence is mediated by rare genetic variation and
by variation in CHRNB4 specifically.

METHODS
Sample Selection
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine
Dependence (COGEND). All members of the COGEND sample underwent a semistructured interview, which assessed smoking behavior, other substance use and
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans
(461 nicotine dependent (ND) cases and 249 smokers with no symptoms of dependence
(controls)) and 2055 European Americans (1062 ND cases and 993 controls). As these
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individuals were ascertained to study nicotine dependence, Fagerström Test of Nicotine
Dependence (FTND) scores (Range= 1-10) were required to be <1 for controls and >4 for
cases. In all cases lifetime maximum FTND score was used. Additionally, to ensure that
all individuals in the study had been exposed to nicotine, all members were required to
have smoked at least 100 cigarettes in their lifetime. Among individuals with FTND
scores >4, 96% (1458/1523) were also nicotine dependent using DSM-IV nicotine
dependence criteria. A total of 352 African Americans (176 ND cases and 176 smoking
controls) and 400 European Americans (200 ND cases and 200 smoking controls) were
sequenced. For African Americans, pools of 88 individuals were used (2 case pools and 2
control pools). For European Americans, pools of 200 were used (1 case pool and 1
control pool). The case pools include individuals with FTND scores > 5 whereas the
control pools include individuals with FTND scores <1. Individuals for case pools were
chosen to select the most severely nicotine dependent subjects in our sample. Follow up
genotyping of SNPs identified and validated in the sequenced individuals was done in the
remaining portion of the COGEND sample (310 African Americans and 1662 European
Americans).
Pooled Sequencing
Pooled DNA sequencing was performed as previously described 120. A schematic of the
technique can be seen in figure 2.1. The concentrations of individual DNA samples were
first measured using Quant-iT™ PicoGreen reagent and pooled in equimolar amounts.
Each pooled DNA sample was then used as the template for the amplification of each
protein coding exon of the CHRNA3, CHRNA5, CHRNA6, CHRNB3 and CHRNB4 genes.
Primers for the amplification of each exon were designed using Primer3 and reference
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sequences were taken from the human genome reference assembly build 36.1 (hg18). In
order to ensure complete coverage of each desired exon, a minimum of 50 bp of flanking
sequence on each side was required for each amplicon. We used Pfu high fidelity DNA
polymerase in all PCR reactions to reduce the identification of SNPs generated as a result
of the PCR (false positive SNPs). After PCR amplification of desired genomic regions,
PCR products were cleaned using QIAquick PCR purification kits, quantified using
Quant-iT PicoGreen reagent and ligated in equimolar amounts using T4 Ligase and T4
Polynucleotide Kinase. At this stage, positive and negative control vectors were
amplified and added to each pool to serve as internal quality standards and to be used in
data analysis. After ligation, concatenated PCR products were randomly sheared by
sonication and prepared for Illumina sequencing on an Illumina Genome Analyzer IIx
(GAIIx) according to the manufacturers specifications. As previously shown by Vallania
et al, 121 an average coverage of 30-fold per allele per pool was shown to correlate to
optimal positive predictive value for the SNP-calling algorithm and was, therefore, the
target level of coverage in this study. In order to obtain sufficient coverage per allele per
pool, we obtained two lanes of Illumina GAIIx sequencing per pool. Coverage per
amplicon was calculated for each pool after the first lane of sequence was obtained and
only those amplicons not reaching 30-fold coverage per allele were included for the
second lane of sequencing.
Sequencing Analysis
For analysis, sequencing reads (36 bp reads) were aligned using an alignment algorithm
developed by Vallania et al. 121 which aligns sequences allowing for 2 mismatches or
indels of up to 4 bp. In order to quantify the specificity and sensitivity of this method,
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positive and negative control DNA were introduced as PCR products in the pooled
sequencing protocol outlined above. As a positive control to estimate sensitivity for
variant calling, a pool of 10 plasmids with a 72 bp insert was generated. One plasmid acts
as the “wild-type” insert, while the remaining nine plasmids contain one or two
synthetically engineered mutations. All ten plasmids were combined such that the allele
frequency of each known mutation would mimic either the allele frequency of a single
allelic variant or ten allelic variants in our human DNA pool. Following mixing of the
vectors, PCR amplification across the insert sequence was performed and the PCR
product was added to the normalized pool of human target PCR reactions during
sequencing library preparation. We then obtained more coverage for each amplicon than
that which was required to detect all variants in this amplified positive control vector pool
in order to ensure a minimal SNP detection false negative rate. As a negative control and
to model the sequencing error rate, 1908 bp of the pCMV6-XL5 plasmid were also
amplified and included. One half of the pCMV6-XL5 plasmid sequence was used to train
the SNP finding algorithm and the other to test the error model. Finally, to identify
variants, in the pooled sequence data we used the SPLINTER algorithm 121. The
SPLINTER algorithm produces a p-value for the probability that a predicted variant is a
true positive. This probability is produced using large deviation theory to quantify the
difference between observed allele frequencies within the sequence data to the
background error rate for the same type of sequence changes seen in the amplified
pCMV6-XL5 plasmid. The error model for one of the sequenced COGEND pools can
been seen in figure 2.2. A p-value cut-off value for each lane of Illumina sequencing was
defined as the value at which all positive controls were identified. Only those variants
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falling below this cut-off value were considered “predicted” by SPLINTER. All protein
coding or splice site variants predicted by SPLINTER were then validated by individual
Sequenom genotyping in each person from the source DNA pools. SNPs validated in the
sequenced individuals were then genotyped in all members of the COGEND sample. All
individual genotyping was performed using the Sequenom platform as described
previously 41.

Association Analysis
Each missense variant as well as the number of carriers of missense variants at conserved
positions for each gene in the genes surveyed was tested for association with nicotine
dependence in African Americans and European Americans using Fisher’s exact test.
Conservation was determined by basewise vertebrate conservation using PhyloP score 122.
A site was called conserved when its PhyloP score was greater than or equal to 2,
corresponding to a p-value of 0.01.The SNP rs56218866 (CHRNB4 S140G) was
excluded from analyses as it had been shown previously to have no measurable effect on
receptor function and did not effect the significance of the association between CHRNB4
carrier status and either nicotine dependence or CPD when taken as a covariate 88. For
analysis of cigarettes per day (CPD), FTND score and withdrawal symptom count in
carriers and non-carriers, Wilcoxon Rank-Sum tests were performed.

RESULTS
In order to identify novel rare variants associated with nicotine dependence, we
sequenced 752 individuals from the extremes of the population distribution of FTND
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scores in 6 pools. The protein coding regions of the 5 human cholinergic nicotinic
receptor subunit genes constituting the gene clusters previously reported to harbor
common variants associated with nicotine dependence (CHRNA5-CHRNA3-CHRNB4
and CHRNA6-CHRNB3) were sequenced on an Illumina GAIIx and analyzed using the
SPLINTER algorithm 121. We obtained greater than 30-fold coverage per allele at all
positions within the 28 amplicons designed to cover the protein coding exons of
CHRNA3, CHRNA5, CHRNA6, CHRNB3 and CHRNB4 and validated 24 (9 novel)
missense variants (Figure 2.3 and Table 2.1). We only attempted to validate missense
variants as these are more likely to have a functional impact than non-coding or
synonymous coding changes. As the SPLINTER algorithm produces a p-value for the
probability that a predicted variant is a true positive, we also genotyped a number of
variants below our cut-off for significance in order to determine the positive predictive
value of the algorithm. A total of 42 variants were genotyped in the sequenced
individuals. Of these, 14 were selected for having probabilities of being true positives just
below our cut-off value. Only 1 of these 14 variants was validated while 24 of 28 SNPs
predicted to be true positives were validated. This produced a positive predictive value of
86%. Additionally, all variants included as part of the amplified positive control vector
were found upon achieving greater than 30-fold coverage at mutated sites (Sensitivity =
100%) and only ~80 sites in the 1908 bp negative control vector were predicted to be
polymorphic (Specificity = ~95%). The majority of validated variants, as expected, are
rare (22/24 = 92% have MAF < 5%) in African Americans or Europeans. In fact, many
are present in only one sequenced individual (7/24 = 29% are singletons). Additionally,
some of the missense variants present in these genes were found at less conserved sites
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(9/25; PhyloP score < 2), suggesting that they are less likely to have a functional impact.
Altogether, we identified 15 variants (4 novel) at conserved sites and used these for
further analysis. Of these, 12 were also predicted to be damaging by Polyphen, SIFT or
both (Table 2.2) 123,124. We determined the frequency of each missense variant validated
from sequencing in individuals from the Collaborative Study on the Genetics of Nicotine
Dependence (COGEND) (710 African Americans and 2055 European Americans) using
Sequenom. We then compared the frequency of each missense SNP as well as the
number of carriers of conserved missense variants in cases and controls for each of the
genes sequenced (Table 2.2). To ensure novel findings, we excluded the SNP rs16969968
from analyses in European Americans as this would overshadow the effects of other
variants in the CHRNA5 gene and because it is common in European Americans
(Frequency= 0.35). We find that two SNPs in CHRNB4 (T91I and T375I) and one SNP in
CHRNA3 (R37H) are associated with decreased risk of nicotine dependence either in
African Americans or European Americans (Table 2.1). Notably, the T91I and R37H
variants are in high linkage disequilibrium (LD) in European Americans (r2 =0.89,
n=710) and African Americans (r2 =0.59, n=2035), making it difficult to determine the
relative contribution of the two variants to the observed association. We found nominal
evidence of association between rare variants at evolutionarily conserved sites and
nicotine dependence at CHRNA5 in African Americans and CHRNA3 in European
Americans.
We find that carriers of rare missense variants at conserved sites in CHRNB4 were
less frequently nicotine dependent compared to non-carriers, both in African Americans
and European Americans (African Americans p = 0.0025, OR = 0.31, 95% CI = 0.31-
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0.72; European Americans p = 0.023, OR=0.69, 95% CI = 0.50-0.95) (Table 2.3). This is
significant for African Americans after Bonferroni correction for multiple tests assuming
one test for each gene studied (p < 0.01). As we are not able to distinguish between the
effects of the T91I and R37H variants, carriers of missense variants at conserved sites in
either CHRNA3 or CHRNB4 are also less frequently nicotine dependent compared to noncarriers (African American p = 0.0035 European American p = 0.012). To determine if
the observed association could be explained by the CHRNA3 R37H alone, we performed
logistic regression including CHRNA3 R37H genotype as a covariate. CHRNB4 carrier
status remained associated with nicotine dependence status in African Americans (p =
0.0025), but not in European Americans (p=0.37). This is most likely because
rs61737499 (CHRNB4 T375I), one of the major contributors to the association SNP in
African Americans, is monomorphic in European Americans. Additionally, we
investigated the possibility that one of the four comorbid DSM-IV defined substance
dependence phenotypes measured in our dataset (alcohol, cocaine, marijuana and opiates)
was contributing to the observed association at CHRNB4. None of these comorbid
phenotypes significantly altered the association results observed between nicotine
dependence and CHRNB4 carrier status in either African Americans or European
Americans when included as a covariate in a logistic regression. These findings suggest
that variants in CHRNB4 and possibly CHRNA3 protect against nicotine dependence and
that this is not due to a correlation between nicotine dependence and other comorbid
phenotypes.
Two groups of common genetic variants within the CHRNA5-CHRNA3-CHRNB4
gene cluster (tagged by rs16969968 and rs588765, respectively) were previously shown
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to affect nicotine dependence risk. To determine if our findings could be due to LD with
either of these variants, we performed logistic regression including each as a covariate.
CHRNB4 carrier status remained associated with nicotine dependence status in African
Americans (p = 0.0048), but not in European Americans (p=0.13) when rs16969968
genotype was included as a covariate. However, we find that CHRNB4 carrier status is
associated with nicotine dependence among carriers of the minor allele of rs16969968
(Fisher’s exact test p=0.03, OR=0.55) in European Americans. CHRNB4 carrier status
was associated with nicotine dependence status in African Americans (p = 0.0031) and in
European Americans (p=0.043) when rs588765 genotype was included as a covariate.
These findings suggest that our observed associations are not due to a correlation
between rare variants in CHRNB4 and previously described common variant associations
in the region.
To ensure that our findings within the African American portion of the COGEND
sample is not due to population stratification, we calculated principal components using
EIGENSTRAT 125. We then performed logistic regression to test the association between
CHRNB4 carrier status at conserved sites and nicotine dependence including the first two
principal components (PC1 and PC2) as covariates. CHRNB4 carrier status remained
associated with nicotine dependence status in African Americans (p = 0.0038).
Additionally, we calculated local admixture using LAMP 126. CHRNB4 carrier status
remained significantly associated with nicotine dependence when we performed logistic
regression including local admixture estimates from the 100kb encompassing the
CHRNA5-CHRNA3-CHRNB4 gene cluster as a covariate (p = 0.0029). These findings
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suggest that the observed association is not due to population stratification, either on a
genome scale or on a local scale.
In order to examine which aspects of nicotine dependence are affected by variants
in CHRNB4, we tested the association between several nicotine related phenotypes in
addition to case status. When we compared the distribution of CPD in CHRNB4
conserved SNP carriers and non-carriers, we observed that carriers also have a lower
mean CPD than non-carriers (African American p = 6.6x10-5, European American p =
0.021) (Figure 2.4). FTND as a quantitative trait was also lower in carriers compared to
non-carriers (African American p = 0.0019, European American p = 0.008) (Table 2.3).
Using DSM-IV criteria to assign nicotine dependence case status we find carriers to have
reduced risk of becoming nicotine dependent in African Americans (p = 0.03) and
European Americans (p = 0.02). As Chrnb4 knockout mice exhibit reduced withdrawal
symptoms upon cessation of prolonged nicotine exposure 90,127, we investigated whether
conserved missense variants in CHRNB4 contribute to withdrawal symptoms among
individuals who attempt cessation. We find carriers of conserved missense variants in
CHRNB4 show fewer signs of withdrawal as measured by the number of withdrawal
symptoms endorsed in African Americans but not European Americans (African
American p = 0.012, European American p = 0.42) (Table 2.3).

DISCUSSION
We find that rare missense variants at evolutionarily conserved sites in CHRNB4
and CHRNA3 protect against nicotine dependence in African Americans and European
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Americans. We do not find an association between rare variants, conserved or otherwise,
and nicotine dependence at the other genes studied (CHRNB3, CHRNA6 and CHRNA5)
in African Americans or European Americans. This may be due to insufficient power
resulting from low minor allele frequencies even after collapsing genotypes within genes.
For instance, the frequency of carriers of missense variants at conserved loci for
CHRNA5 in European Americans is 0.015 while the frequency of such carriers for
CHRNB4 is 0.055. This increased carrier frequency for CHRNB4 was in large part due to
the combined frequency of the two variants (T375I and T91I) which is why we chose to
study these SNPs in vitro (see chapter 4). It is important to note that rare variant
associations are more dependent on stochastic events, namely the sampling of rare allele
carriers from a population, than studies of common genetic variants. It is possible that our
observed associations may be due to chance fluctuations in rare variant allele.
When considering genetic associations in admixed populations, it is important to
insure that findings are not due to subtle population stratification, either on a genome
scale or locally at associated loci. As a result, we calculated both global and local
measures of admixture for each of the African American individuals in COGEND. We
find that neither global nor local admixture is able to account for the association we
observe between rare missense variants at evolutionarily conserved sites in CHRNB4 and
nicotine dependence.
In addition to nicotine dependence, we examined the effect of conserved missense
variants in CHRNB4 on several phenotypes designed to tease apart various aspects of
dependence. Specifically, we find that African American and European American rare
variant carriers smoke fewer cigarettes per day (CPD) and that African American carriers
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experience fewer withdrawal symptoms when compared to non-carriers. These data
suggest that these CHRNB4 variants are likely contributing to the risk of developing
nicotine dependence by allowing carriers to quit more easily, possibly by allowing them
to smoke fewer cigarettes per day to combat withdrawal symptoms. It is difficult to
determine with confidence which aspect of nicotine dependence variants in CHRNB4 are
affecting, however, as each of the phenotypes analyzed are highly correlated in our
sample (r2 from 0.32-0.85) and because our sample was selected to contain the extremes
of the population distribution of FTND score. These findings are in contrast to those of
Wessel et al. who found no association between CHRNB4 variants and nicotine
dependence 51. This lack of association on their part, however, was likely due to lack of
power (they sequenced on 448 individuals) and our association is strongest in African
Americans, a population not sequenced at these genes previously by any group.
In conclusion, we find an excess of conserved missense variants in CHRNB4 in
smokers who are not nicotine dependent compared to smokers who are nicotine
dependent. We hypothesize that these variants act by increasing sensitivity to nicotine
and that these changes lead to our overall finding of decreased risk for nicotine
dependence. Further sequencing of individuals for whom detailed dependence related
information has been obtained is necessary to confirm and elaborate on these findings.
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Figure 2.1. Pooled Sequencing Scheme for COGEND. DNA was quantified and pooled.
The exons and flanking regions for the listed genes were amplified by PCR using PFU
high-fidelity polymerase, pooled and sequenced on an Illumina GAIIx.
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Figure 2.2. Representative Error Model for COGEND Pools. Each line is the average rate
of change of each nucleotide changing to each of the other possible nucleotides for each
of the possible positions within the Illumina sequencing read. Error rates increase
dramatically after 30 cycles as a result of the chemistry used.
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Chapter 3. Identification of rare variants in cholinergic nicotinic receptor genes and
their association with alcohol and cocaine dependence3
ABSTRACT
Previous findings have demonstrated that variants in nicotinic receptor genes are
associated with nicotine, alcohol and cocaine dependence. Because of the substantial
comorbidity, it has often been unclear whether a variant is associated with multiple
substances or whether the association is actually with a single substance. In order to
investigate the possible contribution of rare variants to the development of substance
dependencies other than nicotine dependence, specifically alcohol and cocaine
dependence, we undertook pooled sequencing of the coding regions and flanking
sequence of CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 in 287 African
American and 1028 European American individuals from the Collaborative Study of the
Genetics of Alcoholism (COGA). All members of families for whom any individual was
sequenced (2504 African Americans and 7318 European Americans) were then
genotyped for all variants identified by sequencing. For each gene, we then tested for
association using FamSKAT, which incorporates family structure using a kinship matrix.
For European Americans, we find increased DSM-IV cocaine dependence symptoms
(FamSKAT p =2x10-4) and increased DSM-IV alcohol dependence symptoms
(FamSKAT p=5x10-4) among carriers of missense variants in CHRNB3. Additionally,
one variant (rs149775276; H329Y) shows association both with cocaine dependence
symptoms (p=7.4x10-5, β=2.04) and alcohol dependence symptoms (p=2.6x10-4, β=2.04)
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
3	
  Portions	
  of	
  this	
  chapter	
  are	
  adapted	
  from:	
  Haller,	
  G.,	
  Kapoor,	
  M.,	
  et	
  al.	
  Rare missense
variants in CHRNB3 and CHRNA3 are associated with risk of alcohol and cocaine
dependence (submitted)	
  
	
  

53	
  

when analyzed alone. For African Americans, we find decreased cocaine dependence
symptoms among carriers of missense variants in CHRNA3 (FamSKAT p=0.006). These
are the first results to implicate rare variants in CHRNB3 or CHRNA3 in risk for alcohol
dependence or cocaine dependence.
INTRODUCTION
Twin and adoption studies have suggested that in addition to genetic variants that
contribute to the risk of becoming dependent on a specific drug, there exist genetic
factors underlying a generalized risk for becoming dependent on multiple substances (see
58

for review, 59,60). Epidemiological studies have shown high levels of comorbidity

among alcohol, cocaine and nicotine dependence 128,129. Because of the substantial
comorbidity, it is often unclear whether a variant is associated with multiple substances
or whether the association is actually with a single substance but the extensive
comorbidity leads to apparent association with other substances. Numerous studies have
found that variants altering the function or expression of neuronal cholinergic nicotinic
receptors (CHRNs) alter risk for becoming nicotine dependent and several have shown
effects of variants in nicotinic receptors on risk for both alcohol and cocaine dependence
(see 35 for review). Common single nucleotide polymorphisms (SNPs) in CHRNA5 and
CHRNB3 are associated with nicotine dependence or cigarette consumption 43,130. The
most strongly associated SNP in several GWAS of nicotine dependence, a nonsynonymous change (rs16969968/D398N) in CHRNA5, has also been shown to mitigate
risk for cocaine dependence 61,62. Additionally, a highly correlated group of variants near
CHRNA5, previously shown to alter CHRNA5 mRNA expression in vivo, have been
reported to alter risk for alcohol dependence 41 in addition to nicotine dependence 131.
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GWAS of cigarette consumption has also implicated a group of common SNPs near the
CHRNB3-CHRNA6 gene cluster 43 that have been suggested to be involved in alcohol
consumption, although not with cocaine related behaviors 132. In addition to mediating the
effects of nicotine, neuronal nicotinic receptors have also been shown to alter the cellular
and behavioral effects of alcohol and cocaine independently of nicotine 92-94,97-114.
Evidence from in vitro studies indicates altered response to ethanol upon perturbation of
nicotinic receptors in neurons 95,106-108,115. Studies in rats have shown that partial agonists
of α4β2* or α3β4* nicotinic receptors affect alcohol consumption in vivo 92,95-98,101-105.
These results were confirmed and expanded using transgenic and knockout mice for
various nicotinic receptor genes 93,94,109-114. The physiological and behavioral effects of
cocaine are also dependent on nicotinic receptors. Studies in mice, rats and non-human
primates have suggested that cocaine administration alters nicotinic receptor expression
and in so doing leads to altered response to cocaine 133-136. A recent human trial also
found that the α4β2 subunit partial agonist Varenicline reduced alcohol consumption
among smokers 116. Together these results suggest that altered nicotinic receptor
expression and function likely has an effect on alcohol and cocaine consumption
independent of its effect on nicotine consumption. However, despite the promising
evidence of synergy and cross-substance influences, the combined effects of discovered
common variants have explained only a small proportion of the variance (~5%) in
nicotine dependence and even less of the variance in alcohol or cocaine dependence 45.
Rare variants may explain much of the unexplained heritability of these complex
substance use disorders.
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As a class, rare variants constitute the majority of genetic variation. A recent
survey of more than 4000 exomes from individuals of European and African descent
showed that as much as 86% of coding variants have a frequency less than 0.05% and
that these rare variants are 4 times as likely to be deleterious 137. Many examples now
exist of rare variants contributing to common human diseases (see 47 for review), both in
genes previously reported to cause Mendelian forms of disease and in genes harboring
common SNP associations 48-50. Several studies have demonstrated associations between
rare variation in nicotinic receptor genes and nicotine dependence 51,52,138. An efficient
method of determining the full spectrum of genetic variation in a region and thus the
relative contribution of rare genetic variation to a trait of interest is to sequence pools of
DNA from multiple individuals and to use statistical methods to determine which sites
are polymorphic and at what frequency. We have employed this approach to determine
the contribution of rare non-synonymous variants in the CHRNA5, CHRNA3, CHRNB4,
CHRNA6 and CHRNB3 genes to alcohol and cocaine dependence. My aim in this chapter
is to investigate the hypothesis that rare missense variants in nicotinic acetylcholine
receptor genes contribute in aggregate to risk for alcohol and/or cocaine dependence
independently of nicotine dependence.

METHODS
Sample Selection
COGA Sample
DNA samples were collected as part of the Collaborative Study of the Genetics of
Alcoholism (COGA). All members of the COGA sample underwent a semi-structured
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interview, the SSAGA, which assessed alcohol, cocaine and nicotine use as well as
comorbid psychiatric conditions. The COGA sample utilized in this study consisted of
2504 African Americans and 7318 European Americans. Maximum lifetime cigarettes
per day (CPD) was used as a covariate in all analyses. CPD was calculated by comparing
reports across multiple interviews for an individual and selecting the value of cigarettes
smoked per day that reflected the largest number smoked during the time when the
subject was smoking the most. Only individuals who had at one point in their life smoked
have CPD values. Controls consisted of individuals who had tried a substance but never
became dependent. A total of 287 African American (147 cases and 140 controls) and
1028 European American (480 cases and 548 controls) individuals were sequenced. For
African Americans, pools ranging in size from 44-96 individuals were used (2 case pools
and 2 control pools). For European Americans, pools ranging in size from 68-96
individuals were used (5 case pools and 6 control pools). Follow up genotyping of SNPs
identified and validated in the sequenced individuals was done in the remaining members
of each family represented in the sequenced set of individuals (2217 African Americans
and 6290 European Americans).

COGEND Sample
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine
Dependence (COGEND). All members of the COGEND sample underwent a semistructured interview, which assessed smoking behavior, other substance use and
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans
and 2055 European Americans. The coding regions of the CHRNA3, CHRNB4, CHRNA5,
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CHRNB3 and CHRNA6 genes were sequenced in a total of 352 African Americans (176
ND cases and 176 smoking controls) and 400 European Americans (200 ND cases and
200 smoking controls). Of these sequenced individuals, 120 (34%) of the African
Americans had non-zero DSM-IV alcohol dependence symptom counts, 300 (75%) of the
European Americans had non-zero DSM-IV alcohol dependence symptom counts, 23
(6.5%) of the African Americans had non-zero DSM-IV cocaine dependence symptom
counts and 50 (12.5%) of the European Americans had non-zero DSM-IV cocaine
dependence symptom counts. All missense variants observed in these sequenced genes
were genotyped in all members of COGEND using Sequenom.

Pooled Sequencing
Pooled DNA sequencing was performed as previously described 120,121,138. A schematic of
the sequencing technique used can be seen in figure 3.1. A representative error model for
one of the lanes of sequencing produced for this study can be seen in figure 3.2. As
previously shown by Vallania et al, 121 an average coverage of 30-fold per allele per pool
was shown to correlate to optimal positive predictive value for the SNP-calling algorithm
and was, therefore, the target level of coverage in this study.

Sequencing Analysis
For analysis, sequencing reads (36bp reads) were aligned using an alignment algorithm
developed by Vallania et al. 121 which aligns sequences allowing for 2 mismatches or
indels of up to 4 bp. Positive and negative control DNAs were introduced as previously
described 138. To identify variants in the pooled sequence data we used the SPLINTER
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algorithm 121. All protein coding or splice site variants predicted by SPLINTER were
validated by individual Sequenom genotyping in each person from the source DNA pools.
SNPs validated in the sequenced individuals were then genotyped in all members of the
COGA sample. All individual genotyping was performed using the Sequenom platform
as described previously 139.

Association Analysis
Single missense variants were tested for association in African Americans and European
Americans from the COGA study using linear regression as implemented in the GWAF
package in R using age, sex and CPD as covariates. Each sequenced gene was tested as a
whole for association using famSKAT using age, sex and CPD as covariates. The
GWAF and famSKAT programs were used as the COGA study is family-based and
requires programs that can integrate family information. Associations in COGEND
between alcohol dependence symptom count or cocaine dependence symptom count and
variants in the CHRNB3 or CHRNA3 genes were performed using linear regression in
PLINK using age, sex and CPD as covariates and in R comparing the residuals of alcohol
or cocaine dependence symptom count after correcting for age, sex and CPD in CHRNB3
missense variant carriers vs. non-carriers and CHRNA3 missense variant carriers vs. noncarriers using a Wilcoxon Rank Sum Test. Linear regression and Wilcoxon Rank-Sum
tests were used as COGEND is a sample of unrelated cases and controls.

RESULTS
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We sequenced the protein coding regions of the 5 human cholinergic nicotinic
receptor subunit genes constituting the gene clusters previously reported to harbor
common variants associated with nicotine dependence (CHRNA5-CHRNA3-CHRNB4
and CHRNA6-CHRNB3) in 287 unrelated African Americans (147 DSM-IV alcohol
dependent cases and 140 controls) and 1028 unrelated European Americans (480 DSMIV alcohol dependent cases and 548 controls) as part of the Collaborative Study of the
Genetics of Alcoholism (COGA). DNA pools were sequenced on an Illumina GAIIx and
analyzed using the SPLINTER algorithm 121. In total, we validated 31 non-synonymous
variants (Figure 3.3 and Table 3.1). Of these, all but rs16969968 were rare (<5% MAF), 9
(29%) were novel and 15 (48%) were present in only one sequenced individual. All
variants included as part of the amplified positive control vector were found upon
achieving greater than 30-fold coverage at mutated sites (Sensitivity = 100%) and only 63
sites in the 1908 bp negative control vector were predicted to be polymorphic (Specificity
= ~97%).
We genotyped each missense variant validated from sequencing in every
individual from the COGA study for whom DNA existed, totaling 2504 African
Americans and 7318 European Americans. We then tested for association between nonsynonymous variant carrier status at each sequenced gene and either alcohol or cocaine
dependence symptom count using the family-based Sequence Kernel Association Test
(FamSKAT), which incorporates relatedness into the model using a kinship matrix. Age,
sex and the number of cigarettes smoked per day (CPD) were included in the model as
covariates. To increase the chances of novel findings, we did not include the SNP
rs16969968 in analyses of European Americans or African Americans as it might
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overshadow the effects of other variants in the CHRNA5 gene and because it is common
in European Americans (Frequency= 0.35).
Analysis of European Americans
For European Americans, we find increased DSM-IV alcohol dependence
symptoms (1.3 ± 2.5 vs. 0.65 ± 1.8, famSKAT p= 5x10-4) and increased DSM-IV cocaine
dependence symptoms (2.27 ± 2.7 vs. 2.07 ± 2.4, famSKAT p =2x10-4) among carriers of
missense variants in CHRNB3 (Table 3.2 and Figure 3.4). Further, among the SNPs
comprising the CHRNB3 carrier genotype (S326T, H329Y, K451E and V368M), one
variant (rs149775276; H329Y) was significantly associated in a linear regression model
with increases in both cocaine dependence symptoms (p= 7.4x10-5, β=2.04) and alcohol
dependence symptoms (p= 2.6x10-4, β=2.04) (Figure 3.4). We also tested each gene for
association with CPD using famSKAT and found no significant associations between
CPD and rare missense variants at any of the genes sequenced in this dataset, suggesting
that this is a direct effect of these variants on risk for alcohol and cocaine dependence
phenotypes.
In order to determine if these findings were the result of a correlation between
alcohol or cocaine symptom count and smoking (Figure 3.5 and Figure 3.7), which had
not been accounted for using CPD as a covariate, we tested whether these associations
remained when only heavy smokers (CPD ≥20) were analyzed, as there is no significant
correlation between alcohol symptom count or cocaine symptom count and CPD among
these heavy smoking individuals. Using only heavy smokers (N=2509), the association
between CHRNB3 and alcohol symptom count (famSKAT p = 0.0064) and cocaine
dependence symptom count (famSKAT p = 0.002) remained significant, although
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reduced. No associations between carrier status at any sequenced gene and alcohol or
cocaine symptom count were observed in non-smokers (N=3177). Despite large numbers
of non-smokers, very few non-smokers are alcohol dependent (N=387; 12%) or cocaine
dependent (N=73; 2%), greatly reducing power to detect associations with these
phenotypes in this subset of individuals. Overall, these analyses suggest that rare
CHRNB3 variants are associated with cocaine dependence symptoms and alcohol
dependence symptoms and that these associations cannot be fully explained by comorbid
smoking behavior.
As expected, there are high rates of comorbidity between cocaine dependence and
alcohol dependence in our sample (Figure 3.6). For example, only 3% of European
cocaine dependent cases and ~5% of African Americans cocaine dependent cases in our
sample have no symptoms of alcohol dependence. To determine if the observed
association in European Americans between CHRNB3 variants and either cocaine
dependence symptoms or alcohol dependence symptoms could be explained by a
correlation between the two phenotypes, we included alcohol dependence symptom count
as a covariate in the analysis of cocaine dependence and vice versa. The association
between cocaine dependence symptoms and both CHRNB3 (famSKAT p=0.009) and
rs149775276 (linear regression p =0.002) remained significant when alcohol dependence
was used as a covariate. Using cocaine dependence symptom count as a covariate,
however, CHRNB3 carrier status did not remain significantly associated with alcohol
dependence symptoms (famSKAT p = 0.66). These findings suggest that variants in
CHRNB3 increase risk for cocaine dependence, but only increase risk for alcohol
dependence indirectly by increasing risk for cocaine dependence symptoms or that the
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structure of the dataset is such that one cannot correct for cocaine dependence symptoms
without disrupting all associations with alcohol dependence symptoms. One group of
common SNPs within the CHRNB3-CHRNA6 gene cluster (tagged in our dataset by
rs6474412) was previously shown to affect levels of nicotine consumption and nicotine
dependence 36,43,140. To determine if our findings in CHRNB3 could be due to linkage
disequilibrium (LD) with this variant, we tested for association between rs6474412 and
both alcohol and cocaine dependence symptom count, but in neither case was a
significant association observed. (alcohol symptom count p =0.49, β=-0.03; cocaine
symptom count: p =0.91, β=-0.01). This suggests that our observed associations are not
due to a correlation between rare variants in CHRNB3 and the previously described
common variant.

Analysis of African Americans
For African Americans, we found decreased DSM-IV cocaine dependence
symptoms among carriers of missense variants in CHRNA3 (famSKAT p= 0.006)
(Table3.3). As for European Americans, age, sex and CPD were included as covariates in
the analysis. As there were only two missense variants observed in CHRNA3 in African
Americans, this association was due largely to the association between cocaine
dependence symptoms and one variant (rs8192475; R37H). This variant was previously
shown to decrease risk for nicotine dependence and increase cellular response to nicotine
in vitro 138. The association between CHRNA3 carrier status and cocaine dependence
symptom count remained significant even after alcohol dependence symptoms was
included as a covariate (famSKAT p =0.04).
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To determine if our findings in African Americans could be explained by subtle
population stratification, we calculated principal components using EIGENSTRAT125 and
included the first two principal components (PC1 and PC2) as covariates in the linear
regression. CHRNA3 carrier status remained associated with cocaine dependence
symptom count in African Americans (famSKAT p= 0.01). No sequenced gene other
than CHRNA3 was significant before or after addition of the first two principal
components as covariates in the analysis. Additionally, we calculated local admixture
using LAMP 126. CHRNA3 carrier status remained significantly associated with cocaine
dependence symptoms when we performed linear regression including local admixture
estimates from the 100kb encompassing the CHRNA5-CHRNA3-CHRNB4 gene cluster as
a covariate (famSKAT p= 0.03). No sequenced gene other than CHRNA3 was significant
before or after addition of estimated local ancestry as a covariate in the analysis. These
findings suggest that the observed association is not due to population stratification,
either on a genome or a local scale.
Replication in COGEND
Previous findings from the Collaborative Genetic Study of Nicotine Dependence
(COGEND) have suggested that rare variants in CHRNB4 reduce risk of nicotine
dependence 138. Using previously obtained sequencing data from COGEND 138, we aimed
to determine whether we could replicate the findings from COGA. We tested for
association between alcohol dependence symptom count and cocaine dependence
symptom count and variants in the CHRNB3 and CHRNA3 genes in the COGEND
sample. We used both linear regression and a non-parametric Wilcoxon Rank Sum test as
appropriate for this sample of unrelated subjects. Linear regression using age, sex and
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CPD as covariates revealed that, among African Americans, variants in CHRNB3 are
associated with increased alcohol dependence symptoms (p= 0.004, β=0.48) (Table 3.5).
This was then confirmed using a Wilcoxon Rank Sum test comparing the distribution of
age, sex and CPD corrected alcohol symptom count in CHRNB3 carriers vs. non-carriers
(p= 0.006). There was no association between either alcohol or cocaine symptom count
and CHRNA3 variants among African Americans. More than 60% (N=1685) of
individuals in the COGEND sample have ≥ 1 alcohol dependence symptom, but there is a
severe lack of power to interrogate cocaine dependence symptoms in COGEND because
only ~10% (N=290) of individuals in this dataset have non-zero cocaine dependence
symptoms. We observed no association between either CHRNB3 or CHRNA3 and
cocaine dependence symptoms in European Americans from the COGEND study (Table
3.4).
DISCUSSION
We find that rare missense variants in CHRNB3 are associated with increased risk
for cocaine dependence and alcohol dependence among European Americans and that
rare missense variants in CHRNA3 are associated with decreased risk of cocaine
dependence among African Americans. Upon including comorbid substance
dependencies or proxies thereof (i.e. CPD for nicotine dependence) as covariates, we find
that the observed association with cocaine dependence symptom count remains,
suggesting that this association is not due to correlations between any of the other studied
substances, but that the association between variants in CHRNB3 and alcohol dependence
symptoms among European Americans may reflect the correlation of this trait with
cocaine dependence symptoms in the COGA dataset.
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The association between CHRNB3 and both alcohol and cocaine dependence was
largely due to one variant (rs149775276; H329Y). This variant was rare in European
Americans, but absent in African Americans, partially explaining the lack of association
at this gene among African Americans in the COGA dataset. We were able to replicate
the association between CHRNB3 and alcohol dependence in the COGEND AfricanAmerican sample. It is likely that we were able to observe an association between
CHRNB3 variants and alcohol dependence symptoms but not cocaine dependence
symptoms in COGEND because alcohol dependence symptoms appear more often among
COGEND individuals (~60%) than do cocaine dependence symptoms (~10%).
Additionally, this association was only observed among African Americans individuals in
COGEND. The frequency of CHRNB3 carriers among COGEND European Americans
was exceedingly small (0.6% of individuals) compared to CHRNB3 carriers among
African Americans (~4%).
The association between CHRNA3 and cocaine dependence among African
Americans was due almost entirely to the effect of one variant (R37H; rs8192475). This
variant was previously shown to decrease risk for nicotine dependence and increase
cellular response to nicotine in vitro. Because CHRNA3 R37H is rarer in African
Americans (~0.1%) than European Americans (~4%), the absence of association among
European Americans is not likely to be due to lack of power. However, there may be an
effect of differing genetic background between the two ethnic groups that cannot be
accounted for in our analyses. Additionally, controlling for both global and local
admixture in the African American cohort does not affect the association observed
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between CHRNA3 and cocaine dependence symptom counts, suggesting that this
association is not due to population stratification, however subtle.
For the other genes studied (CHRNB4, CHRNA6 and CHRNA5), no associations
were observed between rare variants and either alcohol or cocaine dependence in
European Americans or African Americans. This may have been due to insufficient
power resulting from low minor allele frequencies even after collapsing genotypes within
genes. Rare variant associations are more dependent on chance observation, namely the
sampling of rare allele carriers from a population, than studies of common genetic
variants. It is possible that our observed associations may be due to chance fluctuations in
rare variant alleles.
There is a debate in the scientific community regarding the relative role of
common versus rare genetic variants in determining an individual’s risk of developing
common diseases. Whether or not the majority of variability in any given trait will
eventually be attributed to common or rare variants is yet to be determined. However, this
and other studies continue to demonstrate the power of rare variant association testing in
the identification and validation of genes contributing to common disease. Moreover, rare
variant associations have the ability to identify specific genes and variants, rather than
large genomic regions. This suggests that in the era of whole genome sequencing,
genome-wide gene-based rare variant associations may be more powerful in identifying
novel susceptibility loci.
In conclusion, we find an association between missense variants in CHRNB3 and
CHRNA3 and alcohol and cocaine dependence symptom counts. Variants in CHRNB3 are
associated with increased risk for cocaine dependence and alcohol dependence, while
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variants in CHRNA3 are associated with decreased risk for cocaine dependence. Both
CHRNB3 and CHRNA3 are associated with cocaine dependence independently of
smoking quantity as measured by CPD, a fact that is not surprising given the role of
CHRN genes in the physiological response to multiple substances and the comorbidity of
nicotine with both alcohol and cocaine use in human populations. We hypothesize that
these variants act either by altering generalized reward pathways, by impacting
impulsivity and related personality characteristics or by altering the effect of alcohol or
cocaine on nicotinic receptors directly. Further sequencing of individuals for whom
detailed dependence related information has been obtained is necessary to confirm and
elaborate on these findings and functional studies will be necessary to elucidate the role
of these genes on the physiological effects of cocaine.
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Pooled Sequencing in COGA
480 European American Alcohol and Drug Dependent
548 European American Controls
147 African American Alcohol and Drug Dependent
140 African American Controls
Pool DNA
and PCR

CHRNA5 CHRNA3 CHRNA6 CHRNB3 CHRNB4
Positive Control
Negative Control

Pool PCR
Products

Ligate, Shear and Sample Prep
Illumina GAIIx
SPLINTER
Follow-up Genotyping in Full Dataset

Figure 3.1. Pooled Sequencing Scheme for COGA. DNA was quantified and pooled. The
exons and flanking regions for the listed genes were amplified by PCR using PFU highfidelity polymerase, pooled and sequenced on an Illumina GAIIx.
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Figure 3.2. Representative Error Model for COGA Pools. Each line is the average rate of
change of each nucleotide changing to each of the other possible nucleotides for each of
the possible positions within the Illumina sequencing read.
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Figure 3.4. Distribution of DSM-IV Alcohol or Cocaine Dependence Symptom Count
among carriers or non-carriers of A) any CHRNB3 variant or B) CHRNB3 H329Y among
European American individuals in the COGA dataset
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Figure 3.5. Distribution of CPD by number of DSM-IV cocaine dependence symptoms
endorsed. Each red circle is proportional to the number of individuals with a given value
of CPD calculated for each number of endorsed DSM-IV cocaine dependence symptoms
endorsed. Proportions per number of symptoms endorsed was used to allow easier
comparison of proportions across the range of symptom count despite differing numbers
of individuals.
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Figure 3.6. Distribution of DSM-IV cocaine symptom count by number of DSM-IV
alcohol dependence symptoms endorsed. Each red circle is proportional to the number of
individuals with a given number of cocaine symptoms endorsed calculated for each
number of endorsed DSM-IV alcohol dependence symptoms endorsed. Proportions per
number of symptoms endorsed was used to allow easier comparison of proportions across
the range of symptom count despite differing numbers of individuals.
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Figure 3.7. Distribution of CPD by number of DSM-IV alcohol dependence symptoms
endorsed. Each red circle is proportional to the number of individuals with a given value
of CPD calculated for each number of endorsed DSM-IV alcohol dependence symptoms
endorsed. Proportions per number of symptoms endorsed was used to allow easier
comparison of proportions across the range of symptom count despite differing numbers
of individuals.
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Chapter 4. Functional characterization of rare variants in CHRNB4 to improve the
association between CHRNB4 and nicotine dependence 4
ABSTRACT
Smoking is the leading cause of preventable death worldwide. As such, effort has been
devoted to determining what genetic variants contribute to smoking risk. Genome-wide
association studies have identified variants in nicotinic acetylcholine receptor genes that
contribute to nicotine dependence risk and follow up studies of these variants suggest that
the same variants may play a role in multiple substance use disorders including alcohol
and cocaine dependence. We previously undertook pooled sequencing of the coding
regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and
CHRNB3 genes and found that rare missense variants in CHRNB4 are associated with
reduced risk of nicotine dependence. Recent in vivo studies have also implicated
CHRNB4 in nicotine addiction: Mice over-expressing Chrnb4 have been shown to
display a strong aversion to nicotine that can be reversed by virally mediated expression
of Chrna5 D398N variant, a variant that reduces nicotinic receptor function, in the medial
habenula 39. It has yet to be determined if rescue with wild-type Chrna5 is possible,
however. Together, these results highlight the importance of understanding the function
of variants in nicotinic acetylcholine receptors and CHRNB4 in particular. Our
sequencing efforts, led to the identification of 18 rare (<5%) non-synonymous variants in
CHRNB4 in a total of 2067 individuals from the Collaborative Study of the Genetics of
Nicotine Dependence (COGEND) cohort. In order to investigate the effect of these
variants, the normal or variant β4 subunit was co-expressed with normal α3 subunit in
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human embryonic kidney 293 cells. Whole-cell voltage-clamp was used to obtain
acetylcholine and nicotine concentration–response curves for each subunit combination.
qRT-PCR, western blots and cell-surface ELISAs were performed to assess differences in
mRNA production, overall CHRNB4 protein expression and cell-surface specific protein
expression levels, respectively. Analysis of these data revealed several variants that
affected nicotine EC50, acetylcholine EC50, maximal response to nicotine, maximal
response to acetylcholine or nicotine efficacy. Nearly all variants tested lowered cellsurface expression. These results highlight the need for detailed functional analysis of
variants using multiple modalities and the advantages to integrating such data into human
genetics.

INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels
formed from numerous combinations of receptor subunits, each encoded by a separate
gene in the human genome. Neuronal nAChR α subunits are encoded by six genes
(CHRNA2-A7, CHRNA9 and CHRNA10) and the β subunits by three genes (CHRNB2B4). A minimum of two α and two β subunits are required to form functional heteromeric
receptors. This is because acetylcholine (ACh) binding occurs at the interface between α
and β subunits. The only subunit capable of forming homomeric receptors is CHRNA7.
Certain combinations of receptor subunits are more common in the human central
nervous system (CNS). There exists profound regional specificity with regard to subtype
expression in the mammalian CNS. The expression of the α3β4* subtype (the asterisk
denotes any one of multiple accessory subunits), for instance, is limited for the most part
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to autonomic and sensory ganglia, medial habenula, fasciculus retroﬂexus and the
interpeduncular nucleus (IPN), while α4β2* receptors can be found almost ubiquitously
throughout the brain 141-143.
Recently, work has been done that suggests that the α3β4* subtype of nicotinic
receptors may largely contribute to nicotine related behaviors by activating the habenulointerpeduncular pathway. The activity of the habenulo-interpeduncular pathway was
recently shown to be increased during nicotine withdrawal and is involved in nicotine
self-administration. Inhibiting α3β4* nicotinic receptors in the habenula reduces nicotine
self-administration while blocking α3β4* nicotinic receptors in the IPN increases nicotine
self-administration 144. Knocking out CHRNA5 results leads to dramatic increases in
nicotine intake, even at high concentrations, and is reversible upon lentiviral expression
of CHRNA5 in the medial habenula77. Further, mice over-expressing Chrnb4 were shown
to display a strong aversion to nicotine, which was reversed upon virus-mediated
expression of the a5 D398N variant in the medial habenula 39. This work suggests that
aversion of nicotine in mouse is regulated by the balanced activity of β4 and α5 nicotinic
receptor subunits in the medial habenula. Additionally, a recent association study of
smoking cessation has shown that variants in CHRNB4 may decrease craving and
withdrawal symptoms 91. These findings suggest that multiple nicotinic receptor subunit
genes likely play a role in the development and maintenance of nicotine dependence and
that variants in these genes may have different and in some cases opposing functional
effects in humans and mice.
Several variants in the CHRNB4 gene have been shown to affect receptor function
using one of these in vitro assays 88. The CHRNB4 variants T91I, R136W, S140G, and
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M467V were each expressed heterologously in Xenopus oocytes and studied using the
two-electrode voltage clamp. These experiments revealed that the R136W and M467V
forms of the receptor had higher sensitivity to acetylcholine and lower EC50 than the
wild-type. The T91I variant was shown to have lower sensitivity to acetylcholine and a
larger EC50. Each of the T91I, R136W and M467V variants also showed greater
desensitization after long-term exposure to low-dose acetylcholine. These results suggest
that variants in nicotinic receptor genes alter receptor function in several ways, but also
that more work needs to be done to fully understand the contribution of variation in the
coding regions of CHRNB4 and other nicotinic receptor genes.
Recently, multiple variants in or near nicotinic acetylcholine receptor genes have
been found to be associated with nicotine related behavior in humans. A nonsynonymous change (rs16969968/D398N) in CHRNA5 is the most strongly associated
SNP in several genome-wide association (GWA) studies of nicotine dependence. This
variant was also shown to affect risk for cocaine dependence, although the risk allele for
nicotine dependence decreases risk for cocaine dependence 61,62. Additionally, variants
near CHRNA5 previously shown to alter CHRNA5 mRNA expression in vivo, alter risk
for both nicotine and alcohol dependence 41,45. A group of common SNPs near the
CHRNB3-CHRNA6 gene cluster were also shown to affect cigarette consumption in a
recent GWAS 43. Sequencing of the neuronal nicotinic receptor genes in large cohorts of
nicotine dependent cases and controls has also found associations between variants in two
nicotinic receptor genes, CHRNA4 and CHRNB4, though we do not replicate the previous
findings in CHRNA4. 52,138. In order to investigate the functional consequences of the
variants associated with nicotine dependence from our study138, we constructed vectors
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harboring variant CHRNB4 alleles, expressed the proteins in Hek293 cells and examined
receptor function using several assays. These results were then incorporated into genetic
association analyses. The goal of this chapter is to characterize the functional impact of
rare variants in the CHRNB4 and CHRNA3 genes observed from sequencing a cohort of
nicotine dependent individuals and non-dependent smoking controls in order to
investigate the hypothesis that modeling the specific functional effects of variants in these
genes, and genes more generally, could be used to improve association analyses of such
variants with disease phenotypes.

METHODS
Generation and expression of constructs
Full-length coding sequences for the human nicotinic α3 (NP_000734.2) and β4
(NP_000741.1) subunits were kindly provided by Dr. J. Lindstrom (University of
Pennsylvania, Philadelphia, PA). Subunits were sub-cloned into the pcDNA3 vector
(Invitrogen, San Diego, CA). Mutations were introduced using the QuikChange kit
(Stratagene, San Diego, CA). The FLAG epitope [DYKDDDDK145] was introduced into
α4 between the 6 and 7 positions of the mature polypeptide using QuikChange. For each
construct the entire subunit coding region was sequenced to verify that only the desired
mutation had been introduced.

Cell culture and transfection.
HEK 293 cells (American Tissue Culture Collection, Gaithersburg, MD) were
maintained in a mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 (1:1,
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also containing L-glutamine and 15 mM HEPES), with 10% fetal bovine serum (Hyclone,
Logan, UT), penicillin (100 units/ml) and streptomycin (100 ug/ml) in a humidified
atmosphere containing 5% CO2 at 37°C. Cells were re-plated in the same medium the
day before transfection.
For physiological and surface ELISA studies, subunits were transfected at a 1:1
mass ratio using Effectene (QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. Briefly, 3 µg of cDNA per well of a 24-well dish was mixed with the
Enhancer and the Effectene Transfection Reagent. The cells were incubated with the mix
for 6 to 18 h. Electrophysiological experiments commenced the following day, while
ELISAs were performed on the third day after transfections.

Cell-Surface ELISAs
Surface ELISA assays were performed basically as described 146,147. Cells were
plated in 24 well tissue culture plates at about 100,000 cells/well. The next day cells were
transfected as described. In each experiment, a negative control (empty pcDNA3) and a
positive control (wild-type subunits) were performed. Five wells were transfected with
each subunit combination in each experiment; 3 were used for ELISA and 2 for a protein
assay. For the ELISA assay, cells were rinsed in phosphate-buffered saline (PBS; 137
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4, pH 7.3) then blocked
for 30 min at room temperature with 4% powdered milk in PBS (milk-PBS). To detect α3
mAb 35 was used as primary antibody (Sigma-Aldrich, St. Louis MO; diluted 1:400 in
milk-PBS) for 1 h at room temperature. Cells were then washed twice with milk-PBS and
incubated with anti-rat IgG peroxidase-conjugated goat antibodies (Sigma, A9037; 1:100
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dilution in milk/PBS) for 1 h and washed with PBS four times. To detect FLAG-tagged
α4, cells were incubated with M2 antibody (Sigma-Aldrich, 2 µg/ml in milk-PBS) as
described and then incubated with anti-mouse IgG peroxidase-conjugated goat antibodies
(Sigma, A9037; 1:100 dilution in milk/PBS) for 1 h. After incubation with secondary
antibody, cells were washed 4 times with PBS, and then assayed using the 1-Step Ultra
TMB-ELISA kit (Pierce, Rockford, IL). Absorbance was read at 405 nm using a
microplate reader (iMark, Biorad, Hercules CA). Total cell protein was assayed from
wells that had been maintained in milk-PBS, then washed twice with PBS before assay
by a bicinchoninic acid method (Pierce). For each experiment, the ELISA signal was
obtained from triplicate wells and the cell protein from duplicate wells.
The surface ELISA data were analyzed as follows. The machine background was
subtracted from each OD reading, then the OD readings were divided by the protein for
that subunit combination. The normalized value for the negative control (pcDNA3) for
that experiment was then subtracted from all values. Finally, to control for variation in
expression between experiments, the subtracted expression levels were normalized to the
positive control (wild-type) value for that experiment. The final value gives an estimate
of the relative expression where a value of 1 indicates identical expression to wild-type
subunits.

Western Blots
To measure CHRNB4 protein levels in HEK293 cell lines transiently transfected
with pcDNA3-empty, pcDNA3-CHRNA3-Wild-Type and pcDNA3-CHRNB4-Wild-Type,
or pcDNA3-CHRNA3-WT and pcDNA3-CHRNB4-Mutant plasmids, we performed
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western blots on cell lysates using a poly-clonal CHRNB4 antibody generously provided
by Dr. Cecelia Gotti. Cells were seeded into 6-well lysine-coated plates and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 1% L-glutamine, and penicillin/streptomycin. Cells were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol incubated in a
humidified atmosphere containing 5% CO2 at 37°C. After two days of growth, each well
of the 6-well plate was used to create a cell-lysate. Cells were lysed with 150ul of lysis
buffer (50 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.25% NP40, 1% TritonX). Total
protein concentration was then measured by BCA assay for each cell lysate. 20ug of
protein from each lysate was then incubated at 95°C for 5 minutes in 1x lamellae buffer
(0.25 M Tris, 8% SDS, 40% glycerol, 0.01% bromophenol blue dye and 20% βmercaptoethanol). Denatured samples were then loaded onto a 4-20% Criterion gel in
TG-SDS buffer (0.01% SDS, 25 mM Glycine, 2.5 mM Tris) and run at 125V ffor 90
minutes. Protein in the gel was then transferred to a nitrocellulose membrane in TG-SDS
buffer containing 20% methanol overnight at 4°C. Blots were then incubated in TG-SDS
containing 4% milk for 25 minutes at room temperature, incubated at room temperature
with a primary CHRNB4 poly-clonal antibody for 90 minutes, rinsed 3x with PBS
containing 1% Triton-X for 5 minutes, incubated with a horseradish peroxidase
conjugated secondary antibody, washed 3x with PBS containing 1% Triton-X for 5
minutes and ﬁnally incubated with the horseradish peroxidase substrate 3, 3, 5, 5, 0tetramethylbenzidine before images were taken allowing for 5 minutes of exposure using
a Syngene western blot imager.
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mRNA Expression
To measure CHRNB4 mRNA production in HEK 293 cells transiently
transfected with pcDNA3-empty, pcDNA3-CHRNA3-Wild-Type and pcDNA3CHRNB4-Wild-Type, or pcDNA3-CHRNA3-WT and pcDNA3-CHRNB4-Mutant
plasmids, RNA was extracted from cell lysates with an RNeasy kit (Qiagen). Extracted
RNA (10 ug) was then converted to cDNA using the High Capacity cDNA Reverse
Transcriptase kit (ABI). CHRNB4 mRNA expression was then measured using sybrgreen
(Invitrogen) using one primer spanning exons 3 and 4 and another primer spanning exons
4 and 5 to ensure only cDNA was amplified.

Whole-cell patch clamp
Cells were plated in 35 mm tissue culture dishes, and maintained and transfected
as described. For recordings, cells were rinsed with recording bath solution (140 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, and 10 mM HEPES, pH
7.4) and cells expressing high levels of surface receptors were identified by a beadbinding technique 86.We used mAb35 (Sigma-Aldrich) to identify α3 and mAb199 for α4
(Sigma-Aldrich). Antibody was adsorbed to immunobeads with a covalently attached
secondary antibody (Invitrogen). The cells were incubated with a suspension of beads for
5 to 10 min with gentle shaking, and cells expressing surface receptors were identified
from the presence of beads bound to the cell. This greatly enhanced our ability to identify
cells expressing measurable numbers of receptors.
Macroscopic currents were recorded using whole-cell voltage clamps described
before 86. A diagram of the whole-cell voltage clamp technique can been seen in figure
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4.1. The pipette (intracellular) solution contained 140 mM CsCl, 4 mM NaCl, 4 mM
MgCl2, 0.5 mM CaCl2, 5 mM EGTA, and 10 mM HEPES, pH 7.4. The drugs were
applied through the bath using an SF-77B fast perfusion stepper system (Warner
Instruments, Hamden, CT). Currents were recorded using an Axopatch 200 amplifier
(Molecular Devices, Union City, CA). The cells were clamped at -60 mV. All
experiments were carried out at room temperature (19–22°C). The current traces were
low-pass filtered at 2 kHz and digitized at 10 kHz. The analysis of whole-cell currents
was carried out using the pClamp 9.0 software package (Molecular Devices).
The basic parameter measured was the peak response to a given concentration of
acetylcholine (ACh) or nicotine. Four second pulses of agonist were applied at intervals
of 30 seconds with continuous application of bath solution between pulses to allow
recovery from desensitization. Concentration-response relationships were constructed by
applying pulses of differing agonist concentration. The data from a cell were analyzed by
fitting with the Hill equation: Y(X) = a(1/(1+{X/k}^n)) where Y(X) is the response to a
concentration X, and the parameters a (maximal response), k (EC50 or concentration
giving half-maximal response) and n (Hill coefficient) were determined by non-linear
regression using SigmaPlot (Systat Software, Chicago IL). To combine data, the
relationships were scaled by the fit maximum. In some cases, it was clear that high
concentrations of agonist produced a reduced response, likely due to open-channel block
by the agonist 148-150. Accordingly, responses to high concentrations that produced a
lower response than responses to lower concentrations were not included in the fit.
Concentration-response data for ACh and nicotine were obtained on different
cells, to minimize the duration of whole-cell recording. Previous work has demonstrated
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that there can be changes in the peak response and/or the desensitization properties of
neuronal nicotinic receptors over the time of whole-cell recording 150,151. Accordingly,
each cell was tested with a high concentration of ACh (usually 1 mM), and this value was
used to normalize the nicotine concentration-response relationship to the overall averaged
ACh concentration-response relationship for that particular subunit combination.
Similarly, some cells were tested with single applications of a high concentration of ACh
and a high concentration of nicotine to obtain estimates for relative maximal responses.
In this case, the relative maximal response to nicotine was normalized to both the mean
concentration-response data for nicotine and for ACh for that subunit combination.
The fact that cells were not randomly selected means that the average response to
a maximal concentration of ACh does not give a direct estimate of the number of
activatable receptors on an average cell and so is not comparable to the surface ELISA
signal. There was a general correlation between the average maximal response and the
ELISA signal.

Drugs, data presentation and statistics.
Unless otherwise noted all chemicals used were obtained from Sigma-Aldrich.
Data are presented as mean ± SE (number of observations). For ELISA studies results
from each experiment constituted one observation; data were obtained in triplicate in
each experiment. For physiological results each cell constituted an observation (i.e. EC50,
or maximal response).
Parameters from fitting the Hill equation were excluded from analysis if the
standard error of any fit parameter for that cell (as estimated by the fitting program) was
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60% or more than the best fitting value. Data from ELISA experiments were excluded if
the expression for the positive control was less than 3-times pcDNA3, indicating a failed
transfection.
Basic statistical computations were made with Excel (Microsoft, Redmond WA).
ANOVA was performed using Stata (StataCorp, College Station TX). Figures were
prepared with SigmaPlot.
The homology model was made by threading the α3 and β4 subunits onto the α
and δ subunits respectively of the Torpedo marmorata cryoelectron microscopic structure
(152; PDB 2BG9) using the SWISS-MODEL web tool (http://swissmodel.expasy.org/).
Structures were visualized and displays generated using Chimera 1.6.2
(http://www.cgl.ucsf.edu/chimera).

Samples and Phenotype
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine
Dependence (COGEND). All members of the COGEND sample underwent a semistructured interview, which assessed smoking behavior, other substance use and
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans
(461 nicotine dependent (ND) cases and 249 smokers with no symptoms of dependence
(controls)) and 2055 European Americans (1062 ND cases and 993 controls). As these
individuals were ascertained to study nicotine dependence, Fagerström Test of Nicotine
Dependence (FTND) scores (Range= 1-10) were required to be <1 for controls and >4 for
cases. In all cases lifetime maximum FTND score was used. All members were required
to have smoked at least 100 cigarettes in their lifetime. Because in our original analyses
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the association between rare missense variants and CPD in African Americans was the
strongest, we used this as our primary sample and phenotype when assessing whether
functional characterization of alleles could improve observed associations. As linear
regression was used and requires normally distributed variables, we log-transformed CPD
such that it was normally distributed. A total of 352 African Americans (176 ND cases
and 176 smoking controls) and 400 European Americans (200 ND cases and 200
smoking controls) were sequenced in the original study. Follow up genotyping of SNPs
identified and validated in the sequenced individuals was done in the remaining portion
of the COGEND sample (310 African Americans and 1662 European Americans).

Association Analysis
Association analyses were performed in R using linear regression incorporating age and
sex as covariates. To analyze carrier status, individuals were coded as either 0 or 1
depending on whether they carried 0 or ≥ 1 missense variants at any position in CHRNB4.
Carrier status was tested in a linear regression against logCPD with age and sex as
covariates. For all variant combinations of multiple CHRNB4 variants occurring in at
least one individual, plasmids were created that harbored both variants. To analyze the
function-weighted carrier status, individuals were coded as either 0 or 1 depending on
whether they carried 0 or ≥ 1 missense variants at any position in CHRNB4 and then the
person’s code was multiplied by the normalized value for each of the tested parameters
(Acetylcholine EC50, Nicotine EC50, acetylcholine maximal response, nicotine maximal
response and nicotine efficacy). These values were then used as the predictor in a linear
regression using age and sex as covariates.
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RESULTS
Pharmacological Profiles of Variant containing α3β4 Receptors
A total of 10 rare missense variants were identified in CHRNB4 as part of the
previous sequencing projects. These variants can be found in many domains of the
mature protein, but many occur within the first extracellular domain (Figure 4.40). To test
the electrophysiological properties of β4 containing nicotinic receptors constructed to
harbor these variant alleles, wild-type α3 and variant containing β4 receptor subunits
were co-expressed in HEK 293 cells. Responses from cells were measured upon exposure
to between 1 and 10,000 µM ACh and subsequently to 1 to 300 µM nicotine.
Representative traces and resultant concentration response curves can been seen in figure
4.41. Concentration response curves for nicotine for each variant can been seen in figures
4.9-4.23. Concentration response curves for acetylcholine can be seen in figures 4.244.39. Several variants show altered response to nicotine. Specifically, nicotine EC50 was
altered for two variants (M456V and K57E) and nicotine efficacy was altered for one
CHRNB4 variants (T91I) when combined with the α3 variant R37H, a variant that almost
always accompanies T91I in individuals of both African and European descent. Values
and statistical significance for all electrophysiological assays can be seen in Figure 4.41,
4.42, 4.45 and tables 4.1, 4.2 and 4.3. No variants observed during sequencing
significantly affected any electrophysiological parameters when expressed with α4
subunits rather than α3.
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Cell-Surface ELISAs
In order to determine the extent to which mutations in CHRNB4 and CHRNA3 alter the
steady-state level of nAChR protein expressed on the cell-surface, we performed ELISAs
on cultured HEK 293 cells two days after transient transfection with constructs
expressing wild-type CHRNA3 and either wild-type CHRNB4 or mutant CHRNB4. A
diagram of the technique can been seen in figure 4.2. Cell-surface expression was
decreased for nearly all variants tested (Figure 4.44, Table 4.3 and Table 4.4.). The
S140G variant is predicted to abolish glycosylation at amino-acid position 138. The S is
third amino acid in the consensus glycosylation signal NXS, where X can be any amino
acid. We hypothesized that the absence of glycosylation at this site results in low cellsurface protein expression of this variant. First, to test this hypothesis, we created a
CHRNB4 expressing plasmid containing an alanine (A) at position 138, rather than the
asparagine (N) required for glycosylation at this site as well as a plasmid containing a
threonine (T) at position 140, predicted to retain glycosylation but change the amino acid
at position 140. Cell-surface ELISAs demonstrated cell-surface protein levels of the
N138A variant to be low and similar in level to the S140G variant while the S140T
variant showed cell-surface protein levels more closely resembling wild-type CHRNB4,
albeit reduced (Figure 4.44, Table 4.3 and Table 4.4.). These data suggest that at least for
the S140G variant, it is ablation of glycosylation at this position that explains the
reduction in cell-surface protein expression of S140G variant receptors. We also observe
a significant correlation between relative cell-surface ELISA results when variant
containing subunits are expressed with α3 or α4 subunits (Figure 4.46) and a significant
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correlation between relative maximal response to acetylcholine and relative cell-surface
ELISA levels when expressed with α3 but not α4 (Figure 4.47).
Western Blots
In order to determine if overall CHRNB4 protein, both intra-cellular and cell-surface, was
altered by the introduction of mutation, we performed western blots on total cell lysates
from HEK 293 cells transiently transfected with wild-type CHRNA3 containing plasmids
and either wild-type or mutant CHRNB4 containing plasmids. Analysis of the band
intensity for each mutant protein provided no evidence of altered total CHRNB4
expression for any of the variant plasmids (Figure 4.3, 4.4, 4.5 and Figure 4.8). Of note,
each of the variants predicted to alter glycosylation at amino-acid position 138 (S140G,
N138A and S138A/S140G) show shifts in their full-length protein band in the expected
direction assuming a disruption of glycosylation (Figure 4.3). Further, these differences
in apparent molecular mass were normalized upon incubation with PNGase to remove all
glycosylation (Figure 4.6 and Figure 4.7).

Association Analyses
To determine if incorporation of results from our functional analyses of all
variants known to exist in our study population could be used to improve power to detect
an association between nicotine related behaviors and variants in CHRNB4, we created a
genotype model weighted based on the predicted maximal nicotine response of each of
the variants. We used each parameter estimated from a variant’s concentration response
curves for nicotine and acetylcholine as well as cell-surface protein level to create
quantitative measures of receptor function that we could assign to each individual based
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on the alleles they harbor. We first performed an analysis simply using carrier status at
any non-synonymous site in CHRNB4 as the predictor variable in a linear regression with
log transformed lifetime maximum number of cigarettes smoked per day (logCPD) as the
response variable and including age and sex as covariates. Using all missense variants,
there is no significant association between carrying at least one missense variant in
CHRNB4 and logCPD (β = -0.038, p= 0.585, r2 = 0.0009) (Figure 4.48). We then took the
subset of missense variants that occurred at genomic positions with at least suggestive
levels of cross-species conservation (vertebrate PhyloP scores > 2). This reduced the
number of variants from ten to six. We observed a modest, but significant association
between carrying at least one missense variant at a conserved site in CHRNB4 and
number of cigarettes smoked/day (β = -0.24, p-value = 0.008, r2 = 0.009) (Figure 4.49).
We then weighted each variant genotype by the value for each of the estimated
electrophysiological parameters (nicotine EC50, acetylcholine EC50, maximal response to
nicotine, maximal response to acetylcholine, nicotine efficacy) or relative cell-surface
expression level. The results of this weighting procedure can be seen in Figures 4.504.55. Weighting in this way by acetylcholine EC50 explained substantially more
phenotypic variance and produced an association that would be considered genome-wide
significant for gene-based associations assuming a multiple test correction for 20,000
genes (β = -0.006, p-value = 6x10-6, r2 = 0.029). These results suggest that substantial
power can be gained by incorporating knowledge of the functional effects of variants into
genetic association analyses.

DISCUSSION
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The goal of this chapter was to characterize the functional impact of rare variants
in the CHRNB4 and CHRNA3 genes observed from sequencing a cohort of nicotine
dependent individuals and non-dependent smoking controls in order to investigate the
hypothesis that modeling the specific functional effects of variants in these genes, and
genes more generally, could be used to improve association analyses of such variants
with disease phenotypes. To do so we performed electrophysiological experiments, cellsurface ELISAs, western blot assays and qRT-PCR to thoroughly describe the effects of
variants in these genes on receptor expression and function. Some variants had little
effect on receptor function. However, most variants had some measurable effect on cellsurface protein expression compared to wild-type. As several variants have strong effects
on cell-surface protein expression despite having no measurable effect on smoking
behavior, it seems reasonable that alterations to protein function are better indicators of
whether or not a variant will affect behavior. Additionally, as the intracellular protein
level is generally much higher than at the cell-surface, individuals heterozygous for
mutations that cause lower cell-surface expression when expressed alone may be
compensated for by their non-variant allele. While many variants perturbed the cellsurface protein levels of the receptors they were incorporated into, none substantially
altered total CHRNB4 protein expression. Additionally, only a small number of the
characterized variants significantly affected aspects of nicotine or acetylcholine response.
The significant relationship between small perturbations of protein function when taken
together and a complex human behavior like nicotine dependence suggests that precise
measurements of allele function are critical. These findings also suggest that it is
important to investigate multiple avenues of protein function alteration to fully
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characterize the impact of variants. Though mildly correlated, the electrophysiological
parameters used in this study likely have distinct effects on cognition and the role of
exogenous chemicals like nicotine in brain chemistry.
Overall, the results from our electrophysiological assays are consistent with
findings reported previously by others 88. These experiments revealed that the R136W
and M467V variants had higher sensitivity to acetylcholine and lower EC50 than the wildtype and that the T91I variant had lower sensitivity to acetylcholine and a larger EC50.
We confirm these results, despite having performed the experiments in transiently
transfected HEK 293 cells and CHRNB4 variant subunits were expressed with CHRNA3
rather than CHRNA4. Though not significant, the Liang et al. study also found the S140G
variant to increase acetylcholine EC50, consistent again with our findings.
We hypothesized that functional characterization of variants could improve power
to detect associations between assayed rare variants in a gene-based burden-like test. In
order to test this, we performed a regression based rare variant burden test in which
variants were weighted in proportion to their effect on each of the following
concentration response curve parameters: acetylcholine EC50, nicotine EC50,
acetylcholine maximal response, nicotine maximal response, nicotine efficacy and cellsurface expression. We find that acetylcholine EC50 was the best predictor of behavior as
measured by log(CPD). No other parameter improved our ability to observe an
association at this locus. Overall, our results suggest that this approach of incorporating
functional information can improve power to detect associations if relevant parameters
are measured and that methods of assaying the functional impact of variants across the
genome will likely greatly improve gene discovery in the era of whole-exome and whole-
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genome sequencing. The reduction in power resulting from large proportions of variants
with little or no impact on protein function or mixtures of protective and risk variants
being included in gene-based burden tests is substantial and will have to be addressed if
we hope to understand the full scope of variation impacting common complex diseases
and traits.
In conclusion, we find that the majority of missense variants in CHRNB4 and
CHRNA3 alter receptor function or receptor cell-surface expression. Further, these
findings may be used to inform genetic association analyses to improve power to detect
signals often obscured by more common neutral or near neutral alleles. These findings
highlight the need for the integration of functional studies into the findings of human
genetics.
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Figure 4.1. Mechanics of whole-cell voltage clamp. First a glass pipette with slight
negative pressure is applied to the outside of a cell. A brief burst of suction is the applied
to break the cell membrane, allowing the inside of the pipette to be continuous with in the
inside of the cell. The degree to which the cell is depolarized upon treatment with an
agonist or antagonist is then monitored. Figure is taken from: http://www.leicamicrosystems.com/science-lab/the-patch-clamp-technique/.
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Figure 4.3. Western Blot of S140G and related variants. N138A, S140G and the doubly
mutated plasmid containing both N138A and S140G, all predicted to affect glycosylation
at residue 138, run more quickly through a polyacrylamide gel than do either S140T or
wild-type proteins, both predicted to permit glycosylation at residue 138.
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Figure 4.4. Total CHRNB4 protein level for variant residues 57-136. Images are
representative of 6 replicate transfections averaged for statistical analyses. Protein levels
were normalized to beta-tubulin levels (bottom).
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Figure 4.5. Total CHRNB4 protein level for variant residues 296-467. Images are
representative of 6 replicate transfections averaged for statistical analyses. Protein levels
were normalized to beta-tubulin levels (bottom).
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Figure 4.6. Total and PNGase digested CHRNB4 protein levels and size shifts for variant
residues related to glycosylation. Incubation with PNGase F normalizes the distance run
on a polyacrylamide gel for variants predicted to affect glycosylation and those that are
not.
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Figure 4.7. Total and PNGase digested CHRNB4 protein levels and size shifts for variant
residues related to glycosylation. Incubation with PNGase F normalizes the distance run
on a polyacrylamide gel for variants predicted to affect glycosylation and those that are
not.
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Figure 4.8. Western blot quantification. Replicates across multiple days of transfection
were averaged and normalized to wild-type CHRNB4 protein level.
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Figure 4.9. Nicotine concentration response curve for wild-type and R37H containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.10. Nicotine concentration response curve for wild-type and K57E containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.11. Nicotine concentration response curve for wild-type and T91I containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.12. Nicotine concentration response curve for wild-type and R136W containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.

	
  

112	
  

&'()*+'#&',-./,'#

%"!!#

!"$!#
:1(;<=>-'#

&%?@A#

!"!!#
%#

%!#

%!!#

%!!!#

%!!!!#

012.*/'#3./2'/45)*./#6789#

Figure 4.13. Nicotine concentration response curve for wild-type and R136Q containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.14. Nicotine concentration response curve for wild-type and S140G containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.15. Nicotine concentration response curve for wild-type and R349C containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.16. Nicotine concentration response curve for wild-type and T375I containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.17. Nicotine concentration response curve for wild-type and M456V containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.18. Nicotine concentration response curve for wild-type and M467V containing
nicotinic receptors. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.19 Nicotine concentration response curve for wild-type nicotinic receptors and
nicotinic receptors composed of R37H CHRNA3 and T91I CHRNB4. Variant (red curve)
response parameters were then estimated and compared to wild-type (black curve)
parameters.
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Figure 4.20. Nicotine concentration response curve for wild-type nicotinic receptors and
nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V
CHRNB4 and R136W CHRNB4. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.21. Nicotine concentration response curve for wild-type nicotinic receptors and
nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V
CHRNB4 and S140G CHRNB4. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.22. Nicotine concentration response curve for wild-type nicotinic receptors and
nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the M467V
and R136W variants. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.23. Nicotine concentration response curve for wild-type nicotinic receptors and
nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the M467V
and S140G variants. Variant (red curve) response parameters were then estimated and
compared to wild-type (black curve) parameters.
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Figure 4.24. Acetylcholine concentration response curve for wild-type and CHRNA3
R37H containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.25. Acetylcholine concentration response curve for wild-type and CHRNB4
K57E containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.26. Acetylcholine concentration response curve for wild-type and CHRNB4
K57E containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.27. Acetylcholine concentration response curve for wild-type and CHRNB4
R136W containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.28. Acetylcholine concentration response curve for wild-type and CHRNB4
R136Q containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.

	
  

128	
  

%!!!!#

&'()*+'#&',-./,'#

%"!!#

!"$!#
:1(;<4=-'#
>%?!@#

!"!!#
%#

%!#

%!!#

%!!!#

Acetylcholine	
  
Concentration	
  (uM)	
  
012.*/'#3./2'/45)*./#6789#

Figure 4.29. Acetylcholine concentration response curve for wild-type and CHRNB4
S140G containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.30. Acetylcholine concentration response curve for wild-type and CHRNB4
G296S containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.31. Acetylcholine concentration response curve for wild-type and CHRNB4
R349C containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.32. Acetylcholine concentration response curve for wild-type and CHRNB4
T375I containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.33. Acetylcholine concentration response curve for wild-type and CHRNB4
M456V containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.34. Acetylcholine concentration response curve for wild-type and CHRNB4
M467V containing nicotinic receptors. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.35. Acetylcholine concentration response curve for wild-type nicotinic receptors
and nicotinic receptors composed of R37H CHRNA3 and T91I CHRNB4. Variant (red
curve) response parameters were then estimated and compared to wild-type (black curve)
parameters.
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Figure 4.36. Acetylcholine concentration response curve for wild-type nicotinic receptors
and nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V
CHRNB4 and R136W CHRNB4. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.37. Acetylcholine concentration response curve for wild-type nicotinic receptors
and nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V
CHRNB4 and S140G CHRNB4. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.38. Acetylcholine concentration response curve for wild-type nicotinic receptors
and nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the
M467V and R136W variants. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.39. Acetylcholine concentration response curve for wild-type nicotinic receptors
and nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the
M467V and S140G variants. Variant (red curve) response parameters were then
estimated and compared to wild-type (black curve) parameters.
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Figure 4.40. Location of variants in a homology model of the α3β4 receptor. A homology
model of the receptor was made by threading the α3 and β4 subunits onto the α and δ
subunits respectively of the Torpedo marmorata cryoelectron microscopic structure 152;
PDB 2BG9) using the SWISS-MODEL web tool (http://swissmodel.expasy.org/).
Structures were visualized and displays generated using Chimera 1.6.2
(http://www.cgl.ucsf.edu/chimera). The subunits are shown as chain trace (α3 red, β4
cyan) with the ACh-binding loops highlighted (α3 yellow, β4 blue). Variants are shown
as stick and ball: α3(R37) (red), β4(K57) - dark blue, β4(T91) - orange, β4(R136) - pink,
β4(S140) - purple, β4(G296) - dark green, β4(R349) - in unstructured region (not shown),
β4(T375) - in unstructured region, β4(M456) - dark green, β4(M467) - light green. None
of the variants are in the transmitter-binding site, nor are they at regions likely to be
points of interaction between subunits. β4(G296) is located in the 3rd and β4(M467) in
the 4th membrane spanning region, but none are located in the channel/gate regions of
the 2nd membrane spanning region.
	
  

140	
  

A

B

Figure 4.41. Responses to acetylcholine and nicotine from cells expressing wild-type α3
and β4 subunits. Panel A shows data from one cell for responses to ACh, and panel B
responses to nicotine (from a different cell). The traces in red are response to the highest
concentration; note that the responses decline more rapidly and show a "tail" of increased
response when the agonist is removed. This is characteristic of channel block by agonist.
On the right, the normalized concentration-response curves are shown; red triangles show
data from the traces on the left, while blue circles show the mean (± SE) data for 20 cells
(ACh) or 9 cells (nicotine). The lines show predictions of the Hill equation:
response = Amp x ([agonist]/EC50)^nHill / (1 + ([agonist]/EC50)^nHill )
where Amp is the maximal response, EC50 is the concentration producing a half-maximal
effect, and nHill is the Hill coefficient. For individual cell data the values used were the
best-fitting values for that cell while for the mean data the values were the mean values
for all fits to data obtained with that agonist. Data for nicotine were normalized to the
maximal response to ACh.
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Figure 4.42. Parameters normalized to that for wild-type, for receptors containing
combinations of α3(R37H) with β4 variants. The panels show the surface expression,
then the relative efficacy for nicotine, the EC50 for nicotine and the EC50 for ACh. Each
pair of bars shows data for α3 or α3(R37H) expressed with the specified β4 subunit. The
symbols on the right show significance of the difference to α3β4, first for α3 with the β4
subunit then for α3(R37H) (ns: >0.05, * <0.05; ** < 0.01; *** < 0.001). (Data are mean+
SE).
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Figure 4.43. Parameters normalized to that for wild-type, for receptors containing
combinations of β4(M467V) with other variants, all expressed with α3. Variants were
combined on the same subunit (e.g. β4(M467V + S140G), or expressed as a 1:1 mixture
of subunits (e.g. β4(M467V)&β4(S140G)). The figure is in the same format as previous
figures.
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Figure 4.44. Surface expression for β4 variants expressed with the α3 or the α4 subunit.
Each pair of bars shows data for the specified β4 subunit expressed with either the α3 or
α4 subunit. The symbols on the right show significance of the difference to expression of
wild-type β4, first for α3 then for α4 (ns: >0.05, * <0.05; ** < 0.01; *** < 0.001). (Data
are mean+ SE).
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Figure 4.45. Physiological parameters normalized for β4 variants normalized to values
for wild-type β4. Each pair of bars shows data for the indicated variant expressed with
either α3 or α4 subunits. The symbols on the right show significance of the difference to
parameters for wild-type β4, first for α3 then for α4 (ND not determined; ns: >0.05; *
<0.05; ** < 0.01; *** < 0.001). (Data are mean+ SE).
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Figure 4.46. Scatter plot of expression of β4 variants with the α4 subunit against
expression with the α3 subunit. Each point shows the mean ± SE, while the solid point
shows the value for wild-type β4. The dashed line shows the line of equality, and the
solid line shows the regression relationship (slope = 1.36, different from a slope of 0 with
P = 0.01). The relationship is consistent with the idea that the variants do not have a
selective effect on expression with a specific α subunit, but rather affect maturation,
general ability to be assembled or trafficking to the surface.
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Figure 4.47. Scatter plots of the average maximal response to ACh for expression of β4
variants against the surface expression. The left panel shows data for variants expressed
with the α3 subunit, the right panel for expression with the α4 subunit. Each point shows
the mean ± SE, while the solid point shows the value for wild-type β4. In each panel the
dashed lines show the line of equality, and the solid lines show the regression relationship.
For expression with α3 the slope = 0.54 that differs from a slope of 0 with P = 0.01. For
expression with α4 the slope = 0.17 that does not differ from a slope of 0 (P = 0.5). The
maximal response was determined with cells selected for high surface expression while
the surface ELISA measures the average surface expression per cell. Accordingly, it
might be expected that variants with low expression would have a larger relative response
compared to wild-type than surface ELISA.
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Figure 4.48. Normalized cigarettes per day among carriers of CHRNB4 missense variants.
Residuals of log transformed cigarettes per day (CPD) after correcting for age and sex
were compared between individuals carrying at least one missense variant in CHRNB4
and those not carrying any missense variants in CHRNB4 using linear regression in R.
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Figure 4.49. Normalized cigarettes per day among carriers of CHRNB4 missense variants
at conserved (vertebrate PhyloP score >2) sites. Residuals of log transformed cigarettes
per day (CPD) after correcting for age and sex were compared between individuals
carrying at least one missense variant in CHRNB4 at a conserved site and those not
carrying missense variants at conserved sites using linear regression in R.
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Figure 4.50. Correlation between Acetylcholine EC50 and CPD. A) The distribution of
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated
acetylcholine EC50. Red line is the estimated linear relationship. B) Box plots of
log(CPD) after correcting for age and sex for each variant or group of variants (i.e.
individuals with two variants) ordered by acetylcholine EC50 value.
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Figure 4.51. Correlation between Nicotine EC50 and CPD. A) The distribution of
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated nicotine
EC50. Red line is the estimated linear relationship. B) Box plots of log(CPD) after
correcting for age and sex for each variant or group of variants (i.e. individuals with two
variants) ordered by nicotine EC50 value.
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Figure 4.52. Correlation between Nicotine efficacy and CPD. A) The distribution of
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated nicotine
efficacy. Red line is the estimated linear relationship. B) Box plots of log(CPD) after
correcting for age and sex for each variant or group of variants (i.e. individuals with two
variants) ordered by nicotine efficacy value.
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Figure 4.53. Correlation between Cell-Surface Expression of CHRNB4 variants when
expressed with CHRNA3 and CPD. A) The distribution of log(CPD) after correcting for
age and sex for each CHRNB4 variant’s estimated cell-surface expression . Red line is the
estimated linear relationship. B) Box plots of log(CPD) after correcting for age and sex
for each variant or group of variants (i.e. individuals with two variants) ordered by cellsurface expression value.
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Figure 4.54. Correlation between acetylcholine maximal response and CPD. A) The
distribution of log(CPD) after correcting for age and sex for each CHRNB4 variant’s
estimated acetylcholine maximal response. Red line is the estimated linear relationship.
B) Box plots of log(CPD) after correcting for age and sex for each variant or group of
variants (i.e. individuals with two variants) ordered by acetylcholine maximal response
value.
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Chapter 5. Conclusions and Future Directions

State of substance dependence research prior to this work
Despite the efforts of many candidate gene studies and several large metaanalyses consisting of >40,000 individuals, very few genes that contribute to the risk of
nicotine dependence or cigarette consumption have been identified. Further, the genes
identified have been excellent candidate genes. The two classes of genes that have been
identified as contributors to nicotine dependence risk are nicotinic acetylcholine receptors,
CHRNA5/B4/A3 on chromosome 15 and CHRNA6/B3 on chromosome 8, and CYP2A6,
the major nicotine metabolizing enzyme, the only non-nicotinic receptor gene to be
significantly associated with the number of cigarettes smoked per day (CPD) at the
genome-wide level. A few sequencing studies had investigated the role of rare variants
in select nicotinic acetylcholine receptor genes prior to the commencement of this work 52.
These studies were limited to cohorts of European Americans and only limited numbers
of individuals were sequenced. The only survey of common variation and nicotine
dependence, as opposed to CPD, was in a tandem candidate gene and genome-wide
survey that examined 3718 SNPs in 348 candidate genes in conjunction with a pooled
genome-wide association study of >2.4 million variants followed by individual
genotyping of ~40,000 variants 22,130. These studies were the first to report the association
between SNPs near CHRNA5/B4/A3 and CHRNA6/B3 with nicotine dependence 36. Like
the state of nicotine dependence research prior to this work, alcohol and cocaine
dependence research had identified only a small number of genes and variants that were
consistently associated with either alcohol or cocaine dependence. Among these are
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several weakly associated variants in a number of gamma-amino butyric acid receptors
(GABRA), alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), the mu
opioid receptor (OPRM1) and bitter taste receptors (TAS) genes (see 63 for review). The
first genome-wide significant association for alcohol dependence was with a missense
variant (rs1229984; R48H) in the ADH1B gene 153. Our group recently demonstrated the
only other genome-wide significant association with alcohol dependence, a bin of
common SNPs tagged by rs12912251 near C15orf53 64. The studies of alcohol
dependence were not as well powered as the studies of cigarette consumption. At most,
these alcohol dependence studies were performed with a few thousand individuals while
the meta-analyses of cigarette consumption were performed with 40-70,000 individuals.
No variant has ever been shown to be genome-wide significantly associated with cocaine
dependence, however. Of course, few studies have been sufficiently powered to detect
effects of the size expected (odds-ratios of 1.1-1.5) and no genome-wide association
studies of cocaine dependence have been performed. Additionally, no sequencing studies
had been done prior to this work for either alcohol or cocaine dependence.
Much work had been done prior to the commencement of this work on
functionally characterizing the nicotinic acetylcholine receptor genes. For instance, mice
lacking various nicotinic receptor genes have been shown to have altered behavioral
response to nicotine 77,90,154. Little work had been done, however, describing the effects of
variants segregating within human populations within these nicotinic acetylcholine
receptor genes. Two such studies characterized a handful of variants in CHRNA3,
CHRNA4 and CHRNB4, but did so in xenopus oocytes and studies of CHRNB4 variants
were done in combination with CHRNA4 rather than CHRNA3 155,156. Work from our
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group has shown striking behavioral effects of knocking in the D398N allele into the
mouse, but this work is yet unpublished. Additionally, no studies have been done wherein
functional information about rare variants has been integrated into association analyses.
Some studies have subset, as we have, on variants with higher prior probability of being
functional (i.e. missense, nonsense, splice-site), but none to our knowledge have
weighted genotypes based on the results from a functional assay.

Dissertation specific aims
As very little of the variance in nicotine dependence risk, and the variance in
nearly all complex traits, can be explained by common SNPs, we began investigating the
potential role of rare genetic variants in risk for this trait. We undertook pooled
sequencing of the coding regions and flanking sequence of the CHRNA5, CHRNA3,
CHRNB4, CHRNA6 and CHRNB3 genes in 710 African Americans (461 nicotine
dependent (ND) cases and 249 smokers with no symptoms of dependence (controls)) and
2055 European Americans (1062 ND cases and 993 controls) from the Collaborative
Study of the Genetics of Nicotine Dependence (COGEND). We then asked whether the
proportion of individuals harboring at least one rare non-synonymous variant at the
subset of amino-acid positions conserved across vertebrate species was different in
nicotine dependent smokers compared to non-nicotine dependent smokers. We
demonstrated a reduced risk for nicotine dependence among carriers of missense variants
at conserved residues in CHRNB4 in African Americans and European Americans.
We then aimed to determine whether rare genetic variation in these genes
influence risk for developing alcohol or cocaine dependence, two conditions highly
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comorbid with nicotine dependence. We again undertook pooled sequencing of the
coding regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6
and CHRNB3 genes in 287 African Americans (147 DSM-IV alcohol dependent cases
and 140 controls) and 1028 European Americans (480 DSM-IV alcohol dependent cases
and 548 controls) individuals from the Collaborative Study of the Genetics of Alcoholism
(COGA). Of these individuals, there were 98 (66%) African American DSM-IV alcohol
dependent cases who were also DSM-IV cocaine dependent and 184 (38%) European
American DSM-IV alcohol dependent cases who were also DSM-IV cocaine dependent.
We then performed follow-up genotyping of all identified non-synonymous variants in all
available members of the families from which the sequenced individuals came, totaling
2504 African Americans and 7318 European Americans. For European Americans, we
found increased DSM-IV cocaine dependence symptoms and increased DSM-IV alcohol
dependence symptoms among carriers of missense variants in CHRNB3. For African
Americans, we find decreased cocaine dependence symptoms among carriers of missense
variants in CHRNA3. These two genes had not previously been implicated in alcohol or
cocaine dependence specifically. The gene cluster containing the CHRNA5, CHRNB4 and
CHRNA3 genes was found to be associated with alcohol dependence and cocaine
dependence, but the linkage disequilibrium bins associated with these phenotypes contain
SNPs that alter CHRNA5 brain mRNA expression (bin tagged by rs588765) and alter
protein function (rs16969968, CHRNA5 D398N), neither implicating CHRNA3 or
CHRNB4 directly.
Finally, we sought to determine the functional impact of rare variants in CHRNB4
harbored by individuals in these two cohorts. All variants observed in at least one
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individual in the COGEND cohort in CHRNB4 (14 variants) were investigated. One
variant in CHRNA3 (R37H) was also functionally tested as it is in high linkage
disequilibrium with another rare missense variant (T91I) in CHRNB4. We found several
variants that alter cellular response either to nicotine or acetylcholine as well as many
variants that alter cell-surface protein expression as measured by cell-surface ELISA
without altering either CHRNB4 mRNA or total β4 protein as measured by western blot.
Further, when we integrate these in vitro findings into a model of association with
nicotine dependence related traits, we were able to substantially improve the association
in both African Americans and European Americans. This work strongly suggesting that
the success of future association analyses in these and potentially many other genes
across the genome, may depend greatly on functional assessment of observed genetic
variation. To my knowledge, no other group has attempted to integrate the results from
function assays directly into association analyses. Many groups, ourselves included, have
performed tests using only variants fitting some number of criteria, for instance variants
that occur in functional domains, that perform above a certain threshold on a functional
assay or occur at evolutionarily conserved sites within the genome, but no group has
integrated quantitative data regarding the functional effect of variants composing the
collapsed genotypes using in their analyses.
These findings support the assertion that variants in or near these nicotinic
receptor genes are capable of pleiotropic effects. Previous work from our group has
shown that the common missense variant in CHRNA5 (D398N, rs16969968) affects both
nicotine and cocaine dependence and that a group of SNPs affecting CHRNA5 mRNA
expression in the human frontal cortex contribute to alcohol dependence risk and nicotine
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dependence risk 45,139. In both the case of CHRNA5 and CHRNA6-CHRNB3, the allele
that increases risk for nicotine dependence lowers risk for cocaine dependence or alcohol
dependence, a fact that makes comorbidity an unlikely cause of the pleiotropy observed.
The results from this dissertation suggest that rare variants in nicotinic receptors can
contribute to multiple substance dependence phenotypes. We do not, however, observe a
rare variant association at any gene and more than one phenotype independently of the
other phenotypes. We observe that rare variants in CHRNB4 affect nicotine dependence
and only nicotine dependence and that rare variants in CHRNB3 affect alcohol and
cocaine dependence. It is possible that these findings are the result of having only
minimal power to detect such rare variant associations, even given the relatively large
numbers of individuals sequenced as part of this thesis.
Overall, this dissertation has identified one novel gene for nicotine dependence
and two novel genes for cocaine/alcohol dependence, that the variants underlying the
association of CHRNB4 with nicotine dependence have a significant effect on receptor
function in vitro and that the magnitude and direction of the functional effect of CHRNB4
variants on acetylcholine EC50 can be used to improve the observed association with
nicotine dependence. These are some of the first results implicating rare variants in the
etiology of human behaviors (nicotine, alcohol and cocaine dependence) and some of the
first results to identify rare variants in genes that do not cause a more severe, Mendelian
form of the complex trait under investigation. For instance, PCSK9, one of the first
examples of a gene containing rare variants contributing to a complex trait, encodes a
protease that reduces low-density lipoprotein (LDL) receptor levels. Mutations in PCSK9
had been previously show to cause dominant forms of hypercholesterolemia, so in many
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ways the association of rare variants in this gene with cholesterol levels was unsurprising.
Our results suggest that the identification of associations with either common or rare
variants with truly complex traits require exceedingly large numbers of individuals (we
sequenced hundreds to thousands of individuals and performed genotyping of observed
variants in thousands of individuals), will require that those individuals be well
characterized phenotypically and will likely also require functional characterization of
observed variants to filter association signal from background noise, i.e. the plethora of
neutral alleles extant in human populations.

Future directions
While one novel gene was found to be associated with nicotine dependence and two
genes were identified that contribute to risk for alcohol and/or cocaine dependence as the
result of this work, additional effort will be needed to further validate these findings and
better understand the contribution of these genes to the phenotypes they affect. This will
likely be done by sequencing of larger numbers of individuals to look for associations at
these loci with substance dependence phenotypes and to functionally characterize
identified associated variants. Further work is necessary to find as of yet undiscovered
genes and variants that contribute to substance dependence risk. Additionally, this work
strongly suggests that some variants that contribute to risk of one substance dependence
may contribute to multiple substance dependences and that further investigation into the
effect of genetic variants on comorbid phenotypes is warranted. The fact that multiple
variants in CHRNB3 contribute to both alcohol and cocaine dependence and the fact that
these variants occur in a gene that harbors common genetic variants associated with both
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nicotine dependence and cigarette consumption, strongly implicates these nicotinic
receptor genes specifically in determining one’s risk of becoming dependent on multiple
substances. In the future, designing a study such that the effects of variants on specific
drugs independently of one another would be ideal. For instance, having an entire sample
composed of individuals with no history of drug use or exposure to any drug other than
the drug under study would ensure that any association observed is due to that specific
drug. Then if you saw the same variant associated with another drug in a cohort designed
similarly, i.e. dependent individuals are dependent only on the drug under investigation,
then one could more conclusively say that the variant has pleiotropic effects on various
substance dependence phenotypes. A design in which cases are only dependent on one
drug, especially if that drug is illegal, may be impossible, however. Currently, studies
have been designed to maximize power to detect associations between genetic variants
and a specific drug but have not excluded individuals dependent on other drugs. This
design has made it difficult to determine the dependence the variant is truly affecting. At
the very least, improved statistical models are required to de-convolute the complex
interactions between these drugs, environmental factors and genetic contributors.
An expanded effort to identify variants in the genes studied here and to identify
variants and associations in an unbiased manner, via whole-exome or whole-genome
sequencing of affected and unaffected individuals, will be necessary to improve our
understanding of how genetic factors contribute to substance dependence risk. Our group
has begun sequencing the genomic regions containing the nicotinic receptor genes,
CYP2A6 and a number of other nicotine metabolizing enzymes in a large number of
individuals from COGEND. We have obtained African American samples in a similar
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ascertainment scheme to that used for COGEND as part of the African American Study
of Nicotine Dependence (AAND) and have begun sequencing this cohort as well. This
effort will comprehensively evaluate the contribution of both common and rare variants
in these regions with respect to their contribution to nicotine dependence risk. While most
of these individuals were sequenced as part of this dissertation, several hundred were
merely genotyped for variants observed in sequenced individuals. It is possible, then, that
the added variants discovered in these newly sequenced individuals will give the rare
variant associations the power needed to observe significant associations between some
of these genes and nicotine dependence. Of course, the next important step in
determining the genetic underpinnings of nicotine dependence is to perform either exome
or whole-genome sequencing in this cohort, or ideally an expanded cohort, to test for
associations between rare variants in each gene across the genome and risk for nicotine
dependence. When sequencing becomes sufficiently inexpensive, this study is an
inevitability. Given the expensive nature of whole-genome sequencing and even exome
sequencing at this point in time, paired with the fact that very large numbers of
individuals are necessary to obtain sufficient power to observe significant genetic
associations either with common variants, collapsed rare variants or rare variants using
statistical methods like SKAT or the c-alpha test, it is likely most efficient to perform
targeted sequencing of a large number of individuals. If one has sufficient funds, however,
performing exome-sequencing in the entire sample of individuals is preferable as it
allows for an unbiased determination of the contribution of rare variants to disease risk.
Despite the extensive in vitro work done as a part of this dissertation, further work
can be done to characterize these variants in vitro. Additionally, it has yet to be
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determined if the variants contributing to the observed associations have an effect on
function and behavior in vivo. In order to further test the functional effect of the
observed variants in CHRNB4, or other genes, in a more suitable context, it is now
possible to derive induced pluripotent stem cells (IPSCs) from fibroblasts obtained from a
skin biopsy. These IPSCs can then be differentiated into neurons by incubating the IPSCs
with specific neuronal differentiation factors. These differentiated cells are capable of
producing action potentials and express markers of various neuronal populations. IPSCs
can be derived from individuals with and without a given genetic variant and the
electrophysiological properties of their IPSC derived neurons can be determined. Further,
current technology including zinc-finger nucleases, TALEN effectors and CRISPR-Cas9,
can be used to alter a specific nucleotide base and compare the properties of cells with or
without a mutation while retaining identical genetic background. This would likely
reduce the signal to noise ratio as variance induced by comparing individuals with
differing genetic backgrounds would no longer be an issue. In order to investigate the
effects of observed variants in vivo, a reasonable experiment would be to construct either
lentivirus or adenovirus constructs that are able to infect live cells and express wild-type
or variant forms of nicotinic receptor subunits as well as GFP as a marker of infection.
Upon infecting interesting brain regions, for instance the medial-habenula or
interpeduncular nucleus, slices could be made and electrophysiological measurements
taken to determine the effect of variants on receptor function in vivo. Additionally, living
mice infected with these constructs can be subjected to nicotine conditioned place
preference testing to determine if expression of variant receptors lead to altered nicotine
preference or aversion. Knockout mice for the receptor subunit under investigation, in
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this case CHRNB4, would be preferable to wild-type mice as all observed CHRNB4
would necessarily be introduced via viral infection. A far more expensive alternative to
this lentiviral/adenoviral approach would be to create knock-in mice with only a single
amino acid changed and then perform the above-mentioned experiments on the resultant
mice. This can now be more readily done with the newly described TALEN or CRISPRCas9 systems of genome editing, but remains far more expensive than the
lentiviral/adenoviral approach. This approach would be preferred generally over
expression of variant forms of CHRNB4 in specific brain regions as it does not suppose a
priori which brain regions are responsible for potential behavioral effects. Additionally,
resultant mice can be propagated without the need to grow viruses or perform stereotaxic
injections. One further disadvantage to this technique is that it is not as easy to investigate
a large number of variants in a short amount of time, a possibility when using the viral
expression technique.
There is much work to be done in the identification of new variants and genes
underlying risk for nicotine, alcohol and cocaine dependence and the characterization of
associated variants and genes in cellular and animal models. Both of these avenues of
investigation undertaken as part of this dissertation remain to be fully explored. It is my
hope that others in our laboratory and other groups will replicate the findings presented
here, expand upon them and utilize the insights drawn regarding the integration of
functional information into association analyses to identify other novel genes involved in
complex diseases.
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